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Development of Ganglioside-Based Assays for the Identification of Botulinum and
Cholera Toxins Utilizing an Evanescent Wave Biosensor
Crystal M. Bedenbaugh
ABSTRACT
An evanescent wave fiber-optic biosensor was used in an effort to develop an
assay for the rapid detection of two biological toxins: cholera toxin and botulinum toxin.
The Analyte 2000 fiber-optic biosensor utilizes a sandwich immunoassay format.
Gangliosides or liposomes are directly adsorbed to the surface of the fiber-optic
waveguide through hydrophobic interactions. The waveguide is exposed to a sample
containing the toxin of interest, then subsequently exposed to a polyclonal detection
antibody conjugated to the fluorophore cyanine 5. Excitation light from a 635nm laser
diode is propagated through the waveguide and fluorescent molecules within
approximately 100nm of the waveguide are excited. The emission light from the excited
cyanine 5 molecules reverberates into the waveguide and is quantitated in pico Amperes
and displayed on a computer.
The exotoxins of Vibrio cholerae and Clostridium botulinum, cholera and
botulinum toxin, respectively, were used for potential assay development. Assay
development utilizing the biosensor was attempted for the detection of botulinum toxin in
buffer. The limit of detection remained too high to generate a positive signal for the
detection of botulinum toxin. Biosensor assays were developed to detect cholera toxin in
buffer, oyster homogenate, pure culture and induction media.
x

A cholera toxin standard curve was generated with a limit of detection of 1 ng/ml.
The values were normalized by setting 100 ng/ml of cholera toxin to a value of 100.
Signals were detected in oyster homogenate spiked at 5 µg/ml as well as unspiked oyster
homogenate. A Western blot showed that there were cross reactive proteins in the oyster
matrix at molecular weights different from those of the cholera toxin. Cholera toxin
production by three strains of Vibrio cholerae with values estimated to range from 100 pg
– 100 ng was detected with the biosensor. Additionally, oysters were harvested from
Tampa Bay and placed in a 10 gallon tank filled with different types of induction media.
The tank was inoculated with Vibrio cholerae and the oysters and induction medium
were analyzed at varying times for the presence of cholera toxin. Vibrio cholerae cells
were viable through 24 hours but no toxin was detectable.

xi

INTRODUCTION
Vibrio cholerae
Background
Vibrio cholerae is a facultative anaerobic Gram-negative curved bacillus that is
motile by a single flagellum. Vibrio cholerae is autochthonous in brackish waters and
marine environments. Vibrio cholerae is the most clinically significant member of the
genus. It is the etiological agent of cholera, an acute bacterial enteric disease.
The organism is ingested with contaminated food or water and, due to the
potentially destructive acidity in the stomach, requires a microbial load of 108 to 1011 for
infection to occur (20). The Vibrio cells will colonize the intestinal tract but they do not
penetrate the intestinal epithelium (20). The pathogenesis of V. cholerae is related to the
production of an enterotoxin, the cholera toxin (CT), which inhibits fluid absorption. The
majority of cholera cases are mild; however, the severest form of the disease is
characterized by rapid loss of body fluids leading to dehydration and shock (20). Initial
symptoms (watery stools, nausea and vomiting) begin to appear 12 to 72 hours after
ingestion of the organism (20).
Historical records indicate that cholera may have first appeared in India around
500 B.C. (24). Since that time, seven pandemics of Vibrio cholerae O1 have occurred.
The most recent pandemic began in Sulawesi, Indonesia in 1961 (24). The emergence of
a new serotype, Vibrio cholerae O139, occurred in October of 1992 in India and
1

Bangladesh. Vibrio cholerae O139 has spread from South Asia to Near-East and
Southeast Asia and has the potential to begin the eighth pandemic (167).
Historical Background
Cholera has been a devastating disease for centuries. Robert Koch was initially
credited for isolating and discovering the vibrio bacillus in May of 1884 (95). Filippo
Pacini studied the organism for 20 years but his research was ignored. Pacini was
posthumously credited for being the first to isolate the bacillus, V. cholerae, in 1854 (95).
In 1965 the International Committee on Nomenclature adopted the formal name Vibrio
cholerae Pacini 1854 in honor of Filippo Pacini and his discovery (95).
Cholera was originally endemic to the Indian subcontinent with the Ganges river
serving as a reservoir (24, 25, 26). Between 1817 and 1961 the world witnessed six
pandemics with 1961 marking the beginning of the seventh pandemic, which is still
ongoing (24). The first pandemic began in Bengal in 1817, spread across India and
extended as far as China and the Caspian Sea before ending in 1823 (24). The second
pandemic (1829-1851) is believed to have begun in Russia and then reached Europe and
the Americas (24). London, Paris, Quebec, Ontario and New York were all affected by
the second cholera pandemic (24). An outbreak in 1849 in New York claimed the life of
the U.S. President James K. Polk on June 15th (45).
During the second pandemic in 1854, a second outbreak occurred in London. Dr.
John Snow lived in London at the time. In 1849 he had proposed that cholera was
associated with contaminated water and food, but was unable to prove his hypothesis
(158). With the emergence of the second outbreak, Dr. Snow demonstrated that the
incidence of cholera was associated with contaminated food and water sources. Dr.
2

Snow conducted one of the first epidemiological studies and plotted the locations where
cholera related deaths occurred throughout the city. He is credited with relating the
spread of the disease to the mixing of drinking water and sewage in Broad Street (150,
158).
Russia and Europe were primarily affected by the third, fourth, fifth and sixth
cholera pandemics with over 1 million deaths occurring in Russia (24). Advances in
protecting the public water supply, chlorination, water mains and the addition of sewer
systems, led to the reduction in the number of cholera cases presented after the sixth
pandemic.
The seventh pandemic began in Indonesia in 1961 and was associated with a new
biotype – the El Tor biotype (24). The classical biotype was responsible for the fifth and
sixth pandemics and may have been connected with earlier pandemics. There is no
definitive evidence available to prove that the classical strain caused the first through
fourth cholera pandemics but it has been associated with their occurrence.
In 1993, a new serogroup of cholera, Vibrio cholerae O139, was identified after a
large outbreak of cholera-like disease in Bangladesh and India (130). The strain of V.
cholerae responsible for the outbreak could not agglutinate in O1 specific antiserum. It
was determined that the organism belonged to a new serogroup (130). In 1994, 94
countries reported incidence of cholera to the World Health Organization (WHO) with
over 10,000 fatalities (64). Twenty-one countries in Latin America reported over 1
million cases with almost 12,000 deaths at the end of 1996 (183). By the end of 2004, 56
countries officially reported cases to the WHO (183, 185). Of the 101,383 cases of
cholera reported during that year, there were only 2,345 deaths (2.3%) (185). Africa
3

reported a total of 95,560 cases in 2004 representing 94% of the global cases of cholera
(185). The number of cholera cases reported to the WHO may be inaccurate with
individuals globally failing to identify cases and officially reporting those confirmed as
cholera.
Classification. Vibrio cholerae is a waterborne bacterium measuring 0.3 microns
in diameter and 1.3 microns in length. Different strains of Vibrio cholerae can be
identified by agglutination with O-specific antiserum. The O antigen is a cell wall
associated component of the lipidpolysaccharide and is used to distinguish between
strains of vibrio. Of the more than 193 currently recognized strains of V. cholerae, V.
cholerae O1 and V. cholerae O139 are the only serotypes pathogenic to humans (18).
The flagellar H antigen is common to many vibrios and all O groups and, therefore, is not
useful in distinguishing one strain of V. cholerae from another (40). The classification
scheme for epidemic and nonepidemic strains of Vibrio cholerae is listed in Table 1.

TABLE 1. Classification of epidemic and non-epidemic associated Vibrio cholerae (78).

Classification

Serogroup

Biotype

Serotype

CT production

Epidemic
associated

O1

Classical and El
Tor

Inaba, Ogawa
and Hikojima

Yes

O139

Not applicable

Inaba, Ogawa
and Hikojima

Yes

All other
strains

Not applicable

Not applicable

Usually not

Not epidemic
associated

4

The O1 serogroup can be subdivided based on antigenic differences in the B and
C components of the O antigen (147). The A antigen is common to all three serotypes
and it is the B or C specific antigen that determines the serotype (147). The antigenic
combinations give rise to the three serotypes: Ogawa, Inaba and Hikojima (Table 2). V.
cholerae O1 strains are able to convert or switch between the three serotypes both in vivo
and in vitro (147). The O139 strain has a unique O antigen and cannot be classified into
one of the three serotypes.

TABLE 2. Antigenic determinants of Vibrio cholerae O1 and O139 serotypes (147).

Serotype

Major O-antigenic determinant

Ogawa
Inaba
Hikojima

A, B
A, C
A, B, C

The O1 serogroup is divided into two biotypes, classical and El Tor, on the basis
of phenotypic characteristics. Biochemical tests differentiate the two biotypes (Table 3).
Both biotypes cause cholera and their differentiation is useful for epidemiological studies.

TABLE 3. Biochemical tests used to differentiation between classical and El Tor
biotypes of Vibrio cholerae serogroup O1 (78).
Biotype

VP test
(modified
with 1%

Classical
El Tor

+

Zone around
polymyxin B
(50 U)
+
5

Agglutination
of chicken,
goat or sheep
erythrocytes
+

Transmission. Cholera transmission occurs via the fecal-oral route through the
ingestion of cells in contaminated food or water. Poor, lacking or non-existant sanitation
systems in impoverished areas allow for contamination of water systems or surface
waters. Use of contaminated water for drinking or in food preparation spreads the
disease.
Raw vegetables (109, 122, 183), molluscan shellfish (40, 109, 122, 123),
crustaceans (40, 109, 122) and rice (109) have been implicated in foodborne transmission
of the disease. Filter- feeding shellfish, such as oysters, clams and mussels, will
concentrate V. cholerae from water into its tissues. These types of shellfish are often
consumed raw, which poses a higher risk of causing illness (40, 77, 98, 122). The first
documented case of cholera in the United States attributed to consumption of raw oysters
occurred in 1973 in Texas (180). Since 1973, 65 cases of cholera caused by V. cholerae
O1 have occurred through 1991 in the United States; most cases were related to the
consumption of contaminated shellfish (12). Sixty-eight cases of cholera were reported
to the CDC between 1995- 2003 and 9% were acquired through the consumption of
seafood harvested from the Gulf Coast (15). After the hurricanes Katrina and Rita struck
Louisiana in October of 2005, 2 cases of cholera were reported (16). Cholera is rarely
seen in the United States and there is a low incidence associated with shellfish
consumption (11, 15, 16).
Cholera toxin. The pathogenesis of cholera is associated with the production of
an exotoxin, the cholera toxin (CT) (192). Bacterial exotoxins are produced by a variety
of bacteria and are a type of virulence mechanism used by microorganism to assist in host
6

invasion and establishment (148). Exotoxins are soluble, heat-labile proteins that can be
toxic in small quantities (93). Exotoxins may be classified into one of three categories
based on structure and mechanism of action: (1) A-B type, (2) membrane disrupting type
and (3) superantigen (148). CT is a heterohexameric AB5 enterotoxin.
A-B toxins are composed of two subunits. The A subunit is responsible for the
enzymatic activity of the toxin, while the B subunit binds specifically to a host cell
surface molecule (148). A-B toxins are classified as simple or compound (148). Simple
A-B toxins, e.g., botulinum toxin, are produced as a single chain and are protealytically
cleaved to produce one A subunit and one B subunit (148). Compound A-B toxins, such
as CT, are composed of multiple B subunits joined to the A subunit by a disulfide bond
(148). The B subunit of an A-B toxin binds to a glycolipid or a protein on the host cell
surface (148). Following binding of the B subunit, the A subunit is cleaved and gains
entry into the host cell (148).
CT is an 84 kD protein composed of one A subunit (27 kD) and five identical B
subunits (11.6 kD each) (103, 191, 192). The B subunits of the CT bind a glycolipid
cellular receptor, ganglioside GM1, on intestinal epithelial cells (33, 60, 143, 145). The
A subunit enters the cytoplasm of the target cell and transfers an ADP-ribose from NAD+
to the α subunit of the Gs protein. The ADP-ribosylated α subunit subsequently activates
adenylate cyclase which leads to an increase in the intracellular concentration of cAMP
(Figure 1) (20, 74, 93). The increase in cAMP concentration causes uncontrolled fluid
and electrolyte flow into the intestine.

7

Cholera toxin
A

Vibrio cholerae

B
Na+, H2O

A
B
GM1

A
ATP

Gsα
AC

cAMP

Epithelial cell

FIGURE 1. Mode of action of cholera toxin. A,B cholera toxin subunits; GM1
ganglioside receptor; Gsα protein; AC adenylate cyclase; cAMP cyclic AMP (74)

The symptoms of the disease are severe diarrhea and dehydration. Of those
infected, approximately 75% are asymptomatic and 25% present symptoms (183). Of
those 25% with illness, 5% have moderate illness requiring medical attention and 2%
face a potentially life-threatening disease (183). Among those infected, initial symptoms
begin to appear 12 to 72 hours after ingestion of the organism (20). The continued
secretion of watery feces, also called secretory diarrhea or rice-water stool, can cause an
infected individual to lose up to 200 ml per kg of body weight per day (20). Secretory
diarrhea may cause death within three hours if left untreated (143). Treatment of the
disease consists mainly of oral rehydration with electrolyte replacement (12). Antibiotics
can be administered to shorten the duration of the illness.

8

The LD50 in mice for cholera toxin is 250 µg/kg, which when extrapolated out
would equal 313 mg/100 lb (53). Consequently, a high concentration of CT is required to
cause illness in humans. Studies with American volunteers demonstrated that oral
administration of up to 1011 viable virulent V. cholerae led to virtually no signs or
symptoms of cholera. Furthermore, cells could rarely be recovered from feces (20, 49).
However, if stomach acid was neutralized with sodium bicarbonate, then 103 viable
organisms could to cause the disease (49). Another study of American volunteers
revealed that an oral dose of 2.5 µg of purified CT caused no illness, whereas a 5 µg dose
resulted in 1-6 L of diarrhea in 80% of volunteers and a 25 µg dose resulted in 22 L of
diarrhea in 100% of volunteers tested (88).
The pathogenesis of cholera is almost exclusively dependant on cholera toxin
production with 95% of O1 and O139 strains possessing CT producing capabilities (18,
20, 50). The two most important virulence factors of V. cholerae are the presence or
production of CT and the toxin–coregulated pilus (TCP) (18, 20, 34, 58, 120, 179). The
ctxAB genes-the genes encoding cholera toxin- are located on the CTX element, which is
part of the genome of a filamentous bacteriophage, CTXФ (18, 20, 34, 58, 120, 149,
179). The receptor for this phage is TCP, which it uses to infect V. cholerae cells (18, 20,
34, 58, 120, 179). Once a cell is infected, the CTXФ can become a lysogen or replicate
extrachromosomally as a plasmid (34). The tcp gene-the gene encoding the toxincoregulated pilus- is part of the V. cholerae pathogenicity island (VPI), (18, 20, 34, 58,
120, 149, 179). Research indicates that the VPI is of bacteriophage origin as well (18,
20, 34, 58, 120, 149, 179). The current hypothesis is that nontoxigenic strains of V.
cholerae acquire the VPI through horizontal gene transfer, thus providing nonvirulent
9

strains with the ability to acquire the CTXФ and toxin producing capabilities (18, 20, 34,
58, 120, 179). The acquisition of the ctxAB and tcp genes makes it possible for the
evolution of pathogenic strains from previously nonpathogenic strains of V. cholerae (18,
20, 34, 58, 120, 179).
Iron. Most bacterial organisms require iron to synthesize cytochromes and need
to sequester iron from the environment. In natural waters, V. cholerae must utilize a
complex system for iron acquisition and in vivo the organism is forced to compete against
animal hosts for iron. Humans main utilization of iron is in the proteins hemoglobin and
lactoferrin. Iron can be a limiting factor in microbial growth. In order to chelate iron
from host and environmental water systems, V. cholerae utilizes a variety of ironchelating siderophores to take up insoluble iron (49, 79, 100). It is still questionable
whether siderophores are required for increased expression of CT.
ToxR regulon. The regulation of the ctx and tcp genes are controlled by the ToxR
regulon (Figure 2) (34, 58, 131, 149, 179). Expression of these genes is transcriptionally
regulated by a cascade system of regulatory proteins: ToxR, ToxS and ToxT (58, 149,
179). In 1987, Miller et al. (107) presented the currently accepted model that indicates
that the ToxR regulon senses environmental signals and undergoes a conformational
change that activates transcription of the other genes - ctxAB, tcpA and toxT - in the
regulon (20, 58, 131, 149). ToxR is stabilized through interactions with the ToxS protein
and activates transcription of the ctxAB operon and toxT gene (20, 58, 131, 149). ToxT
activates the transcription of tcp and ctxAB (20, 58, 131, 149). External environmental
conditions that influence virulence include temperature, osmolarity, medium
composition, pH and oxygen tension (20, 58, 131, 149, 179). It is not clearly understood
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how the environmental signals and sensing occurs, but studies indicate that the ToxR
regulon is influenced by environmental factors including the unknown in vivo conditions
of the human host (20, 131). Further analysis is needed with respect to the role of
environmental signals and their influence on the CT virulence genes and their expression
under the control of the ToxR regulon (20, 58, 107, 131).

ToxR

ctxAB

toxT

A+B
ToxT

tcpA

FIGURE 2. ToxR regulon. Arrows indicate transcription activation (148).

Disease control. Cholera is strictly a human disease and is not pathogenic to
animals (5). The WHO’s current recommendations for disease control focuses on
preventing fecal contamination of water, implementing personal hygiene practices and
managing cases with oral and intravenous rehydration therapy (184). An effective
sanitation system is paramount for the control of cholera transmission. In
underdeveloped countries where sanitation systems are not at the forefront of public
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health concerns, cholera becomes epidemic. Transmission is normally associated with
contaminated water, however in areas where there is a lack of clean water the disease can
also be spread through households via contaminated foods.
A parenteral cholera vaccine can be administered to those living in or traveling to
an area where cholera is endemic (22). However, the vaccine is not very effective,
provides limited immunity and is short-lived – approximately 6 months (22). An orallyadministered inactivated cholera vaccine has been field tested in Bangladesh and offers
immunity substantially longer than the parenteral vaccine (22). However, the CDC does
not currently recommend the use of a vaccine and suggests those traveling to areas with
prevalent cholera cases to seek the advice of their doctor (12).
In confirmed, severe cases of cholera tetracycline, doxycycline, furazolide,
trimethoprim-sulfamethoxazole, erythromycin and chloramphenicol therapy can be
administered to shorten the length of infection (183, 184). Oral rehydration therapy of
water, sugars and salts is normally recommended by the WHO (183, 184). With prompt
and adequate care, fatalities due to cholera can be minimized to less than 1% (183).
Ecology and Marine Adaptations
Vibrio cholerae is a ubiquitous aquatic organism of brackish and marine
environments. It was believed that humans were the natural reservoir of V. cholerae;
however, the ocean may actually be the reservoir for the organism (25, 26). V. cholerae
is found in association with phytoplankton and zooplankton (95). A set of complex
ecological interactions exists between cholera, phytoplankton and zooplankton that are
required for the growth, proliferation, expression of virulence and transmission of V.
cholerae in the ocean environment (95).
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Survival in the environment. The ability of the organism to survive in food and
water is dependent upon several variables. Growth of V. cholerae can be suppressed by
the presence of other microflora (77). Other organisms can out compete V. cholerae for
nutrients and required growth factors therefore causing limited or no growth. There are
various abiotic factors that affect the survival of the organism, including temperature,
salinity, sunlight, pH and other microflora (Table 4). The most important physical factor
that has a direct effect on the ecology and growth of V. cholerae is temperature (95).
During the warmer months, higher levels of V. cholerae occur in the water column,
which makes it is easier to isolate the organism (95). Changes in salinity, water
temperatures and possible seroconversion contribute to unfavorable growth conditions
(95). Vibrio cholerae grows optimally within a salinity range of 2-14 g per L (26). The
ability to tolerate fluctuations in salinity allows V. cholerae to survive and grow in
brackish and marine waters.
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TABLE 4. Factors affecting the survival and growth of V. cholerae in the environment
(137).

Factor
Temperature
Salinity
Sunlight (UV light)
pH
Other microflora

Effect
Growth of V. cholerae above 10°C
Growth of V. cholerae, best survival at 0.25-3 %;
optimum at 2%
Reduces survival
Optimum 7.0-8.5
Survival suppressed by competitors

The role of climate change in the survival and growth of V. cholerae is still under
investigation. Colwell used remote sensing imagery systems to study the seasonal
fluctuations in V. cholerae growth in marine waters (25). Studies in Bangladesh
indicated that cholera outbreaks occurred after sea surface temperatures and heights
peaked (25). Temperature models indicate an increase in global temperatures may occur
in the next 100 years. Without efficient public health measures an increase in global
temperature could lead to an increase in the range and prevalence of V. cholerae (95).
Lipp et al. proposed that CTXФ induction and propagation could increase with increased
UV intensity (95). It is also important to take into account natural weather patterns;
however, it is difficult to predict the impact systems such as the El Nino Southern
Oscillation (ENSO) have on V. cholerae growth (95).
When environmental conditions are unfavorable, Vibrio cholerae enters into a
viable but nonculturable (VBNC) state with altered cell morphology (7, 27, 31, 73, 187).
Not only do cells retain viability, but the genes responsible for pathogenicity and
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virulence remain intact and can be expressed as well (17, 28). VBNC cells are detectable
by molecular methods or fluorescent microscopy when conventional laboratory methods
fail (8, 54, 66). During nutrient deprivation, elevated salinity and/or reduced
temperature, the organism enters into a state of dormancy. The shape normally
associated with V. cholerae, a bacillus, becomes smaller with an ovoid or coccoid
morphology (73). The VBNC state in Gram-negative organisms has been equated to the
spore state in Gram-positive cells (141).
Association with marine organisms. Cholera has been found in association with a
variety of aquatic organisms. It has been suggested that there is a complex relationship
between the growth of phytoplankton, algal plants, zooplankton and the growth of V.
cholerae in an aquatic environment (Figure 3).
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Abiotic conditions (Temperature, pH,
Fe3+, salinity, sunlight) favor growth
of V. cholerae and/or plankton

Aquatic plants and algae
grow, allowing growth of
plankton which helps to
promote growth and survival
of V. cholerae.

Other factors which
influence survival,
proliferation and
transmission of V. cholerae:
Changing weather patterns
Sanitation systems
Endemic V. cholerae

Zooplankton, copepods and other
crustaceans feed off of plankton
and aquatic plants. V. cholerae
grows in association with
copepods and proliferate as
commensals with the zooplankton

V. cholerae is transmitted to
humans with the ingestion
of water contaminated with
V. cholerae or V. cholerae
attached to zooplankton

FIGURE 3. Abiotic and biotic factors which influence Vibrio cholerae growth and
transmission (95).

Vibrio cholerae has been found in association with a variety of marine organisms
including cyanobacteria (69, 95), diatoms (101), green algae (69), oysters (77, 98) and
copepods (65, 67, 95). The abiotic factors listed in Figure 6, temperature, pH, Fe3+,
sunlight and salinity, directly affect the growth of plankton and aquatic plants. (95).
Plankton growth is stimulated by temperature, nutrients and sunlight. Proliferation of
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algae and aquatic plants increase the survival and proliferation of cholera cells and
provides a food source for zooplankton communities. Research indicates that an
association with green algae increases CT expression in V. cholerae (69). Zooplankton
feeds off of the plankton; therefore, an increase in plankton causes an increase in
zooplankton.
Vibrio cholerae can colonize different substrates due the production of multiple
enzymes (31). In environmental waters, V. cholerae produces the enzyme chitinase
which assists in its growth on chitin surfaces such as those associated with copepods (26,
31, 46, 127). V. cholerae will colonize copepods (Figure 4) at the oral region and the egg
sac (67). In the human host, mucinases are produced which enable the organism to
penetrate the mucous barrier covering the gastrointestinal epithelium (31, 127). V.
cholerae will multiply until bacterial cells cover the entire egg sac. V. cholerae feeds

Egg sac

~ 1 mm
FIGURE 4. Copepod with egg sac (144).
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off of the chitin substrate of the egg sac and persists on the surface of the copepod for
extended periods of time. As the eggs reach maturity V. cholerae synthesizes chitinase
(113, 114). The chitinase dissolves the egg sac causing the copepod eggs and V. cholerae
to be released into the aquatic environment. V. cholerae can also colonize the gut of
copepods. It has been proposed by Singleton et al. that during its association of the
copepod CT production by V. cholerae serves an environmental role in osmoregulation of
the copepod (157).
While the bacteria are attached to the copepod, they are provided with a large
surface area, substrate, nutrients, protection from low temperatures and acidic conditions,
and a means of transport through the environmental water system throughout the life
cycle of the copepod (26).
There is a direct correlation with the number of copepods and the number of V.
cholerae in the environment. Large populations of copepods will aid in the proliferation
of large numbers of V. cholerae. With high numbers of V. cholerae in the water, filter
feeding organisms, e.g., oysters can and will concentrate the organisms (98, 122, 164).
In impoverished areas where cholera is endemic and sanitation conditions are
poor, there is a direct relationship between zooplankton populations and cholera
incidence (95). In areas of endemnicity, the V. cholerae and the copepods remain in the
water due to weather and circulation patterns. In areas of endemnicity such as
Bangladesh, due to seasonal weather patterns of this region, seasonal increases in
zooplankton are followed by increased numbers of cholera cases (95). Individuals in this
area drink contaminated water containing the copepods harboring the V. cholerae cells.
Huq et al. demonstrated that filtering copepod contaminated water through a sari or nylon
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cloth significantly reduced the number of cholera cases by approximately 52% (65). In
areas such as Japan where there are adequate sanitation facilities and cases of cholera
appear sporadically, there is no direct correlation between increases in zooplankton and
cholera cases (176).
The ecology of cholera is related directly to human disease. One of the initial
problems with understanding epidemics of cholera was identifying V. cholerae’s natural
reservoir. Researchers were initially troubled because V. cholerae could not be cultured
from the environment between periods of cholera outbreak. With the discovery of the
VBNC state, scientists began to understand the cholera paradigm. Using remote sensing
technology, Colwell has studied the ecological relationships between V. cholerae and
marine organisms (25). Filter-feeding organisms in water with high concentration of
cholera cells concentrate the organisms in their tissues. Humans harvest and often eat
these filter-feeding organisms raw thereby leading to illness. CT production has been
shown to occur in association with algae, in the gut of the copepod, or in the intestine of
the human host. Production of CT in each relationship ultimately benefits V. cholerae:
allowing its survival, growth and release into the environment.
Detection of Vibrio cholerae and Cholera Toxin
Vibrio cholerae. The most common laboratory procedure for recovery of V.
cholerae from environmental samples and stool cultures involves conventional laboratory
techniques (Figure 5) (41, 78). Optimum growth occurs at 37°C and the organism can
survive at ambient temperatures for approximately 5 days (11, 137). The organism grows
quickly at a pH of 7.0-8.5 but can survive alkaline conditions in the range of 6.0-10.0
(137). Many vibrios - collectively all species of Vibrio - are halophilic and require salt or
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are stimulated by the addition of it to growth medium (132). Cells are typically enriched
in alkaline peptone water (APW, pH 8.5) for 6-8 hours at 37°C or plated directly onto
thiosulfate citrate bile sucrose agar (TCBS). TCBS, a selective medium used for the
isolation of vibrios, offers several benefits: (1) commercial availability, (2) does not
require autoclaving, (3) is highly selective for Vibrio spp. and (4) contains sucrose for the
differentiation of sucrose fermenters (V. cholerae) from nonfermeters (78). After
isolation on TCBS, isolates are streaked onto a nonselective medium, such as tryptic soy
agar (TSA), followed by agglutination reactions with specific antiserum and other
biochemical tests.

Direct

Enrichment

TCBS

Optional
Screening
Tests

Nonselective medium

String
Oxidase
KIA or TSI
Arginine or Lysine

V. Cholerae O1
Polyvalent antiserum

Ogawa and Inaba
Anitsera

FIGURE 5. Procedure for recovery of Vibrio cholerae from fecal specimens (78).
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The most probable number technique (MPN) is often used in association with
biochemical tests to estimate population numbers in complex matrices, such as soil and
food (122). Cells are enriched in APW, plated on TCBS and estimated population sizes
determined from a standard MPN table.
Conventional laboratory techniques are inadequate for detection of vibrios in the
VBNC state. Molecular methods and fluorescent microscopy are used to detect VBNC
cells (8, 66, 96). Rapid detection methods such as PCR are commonly used for the
detection of viable and VBNC V. cholerae cells (21). Nucleic acid-based methods can be
nonquantitative (42, 48, 64, 75, 80, 152) and require visualization of PCR products
through electrophoresis (98). Alternative PCR methods such as TaqMan PCR allow for
near real-time detection and are quantitative (98). The inherent weaknesses with this
molecular method includes the inability to determine culturable cells from VBNC cells,
PCR inhibition and the ability to only detect four genes in a single reaction (98, 122).
DNA microarrays (182) and multiplex PCR (136) are also used to identify V. cholerae.
Detection of cells does not give an indication of virulence. The Y-1 mouse
adrenal cell assay, ELISAs, rabbit ileal loop assay and the commercially available
immunoassay (VET-RPLA, Oxoid, Inc. Ogdensburg, NY) are used to test for
enterotoxigenicity of V. cholerae (41, 108, 112, 126). The Y-1 mouse adrenal assay is a
tissue culture based method which relies on morphological changes in cell shape of the
mouse cells for determining the presence of CT (99). It is important to note that cholera
toxin production is different in vivo versus in vitro (112). A strain of V. cholerae that
may produce toxin in the human small intestine or the mouse adrenal cells may not do so
under a different set of conditions (112). Unfortunately, the perfect assay does not exist
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with an ideal set of cultural conditions that allows different strains of V. cholerae to
maximize CT production (112).
ELISAs with different biological recognition elements – antibodies and
gangliosides- are commonly used to detect CT (60, 61, 145). The limit of detection
(LOD) utilizing a strictly antibody based technique is 0.09 µg/ml (61). Results using
gangliosides as a capture molecule and antibodies as detection molecules have produced
limits of detection in the range of 40 ng/ml to 1 µg/ml in sandwich immunoassays using
an array biosensor with antibodies directed against rabbit and goat respectively (143).
Dawson reported a limit of detection of 100 ng/ml when using GM1 as a capture
molecule in a sandwich ELISA format (35).
The rabbit ileal loop assay is a time-consuming and cumbersome biological assay
(36, 76). Typically, adult rabbits are starved for a period of 24 hours, then while still
alive a loop of bowel is ligated and injected with live V. cholerae. At autopsy 24 hours
later, the ileal loop is measured in length and volume for the production of CT.
CT. The commercially available reverse passive latex agglutination assay is
simple to use and has a limit of detection of 1-2 ng/ml of CT (112). The assay requires
induction of CT production in an enrichment broth followed by subsequent detection of
the toxin.
If the goal is to rapidly detect CT, then the method employed should detect CT
and not the cells. Very few assays directly assay for CT in a sample matrix in lieu of V.
cholerae cells. One assay, the bead-ELISA can directly detect CT in stool samples at a
limit of detection between 26 pg/ml and > 100 ng/ml (129). The beads are the solid
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phase component of the assay and are coated with an anti-CT antibody. The assay is
performed in a test tube in a sandwich immunoassay format.
The methods described previously for the direct detection of cholera toxin are
especially valuable because it is the toxin that is responsible for the pathogenicity of the
organism. However, conventional methods used to enrich for cells and then assay for CT
can be time consuming and can give inaccurate results with respect to toxigenicity due to
the absence of expression of necessary genes (112). When the cells are taken from the
environment and then enriched and grown in the laboratory under ideal conditions,
specific genes can be turned on, off, rearranged or lost in the process (126). A rapid,
sensitive and specific assay is necessary for the direct detection of CT.
Clostridium botulinum
Background
Clostridium botulinum spores are ubiquitous in soils and aquatic sediments
worldwide (159). The bacterium is a Gram-positive obligate-anaerobic sporulating rod
that measures 0.5-2.0 µm in width by 1.6-22.0 µm in length. Clostridium botulinum is
the etiological agent of food-borne botulism, an intoxication caused by the ingestion of a
potent exotoxin, botulinum toxin (148). Botulinum toxin is a neurotoxin and is classified
into seven different serotypes, A-G, with types A, B, E and F causing the most serious
disease in humans: botulism (68, 84, 159, 163, 181, 190). Botulism is a paralytic illness
caused by the action of the neurotoxin at the vertebrate neuromuscular junction (23). The
neurotoxin blocks the release of the neurotransmitter, acetylcholine, at the peripheral
cholinergic nerve endings leading to respiratory and musculoskeletal paralysis (23, 102).
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There are three main kinds of botulism: (1) foodborne botulism caused by the
ingestion of preformed toxin; (2) wound botulism caused by toxin produced from a
wound infected with C. botulinum; and (3) infant botulism caused by consuming the
spores of the bacterium which sporulate in the intestines and release toxin (68, 84, 102,
124, 140, 159, 163).
Virulence factors. The neurotoxin produced by C. botulinum is the most potent
biological toxin known with a minimum lethal dose in monkeys of 0.5 ng when
administered orally (53), 0.00625 ng in mice when administered intraperitoneal (59) and
an estimated LD50 in humans of 1 ng/kg for type A toxin (53, 63).
All seven neurotoxins are similar in their mode of action and are simple A-B
toxins. The toxin is produced as a single protein chain and then protealytically cleaved to
produce one A subunit and one B subunit (148). The complete toxin has a molecular
weight of approximately 150 kD and is composed of one heavy chain (B subunit) and one
light chain (A subunit) linked by a disulfide bond (84). The active toxin heavy chain
(approximately 100 kD) is responsible for the recognition of specific neuron receptors
and mediates the internalization of the light chain into the cytosol (68, 124, 140, 163).
The light chain (approximately 50 kD) is responsible for the intracellular activity;
blocking the release of acetylcholine at the neuromuscular junction leading to flaccid
paralysis (68, 124, 140).
The action of the neurotoxin is caused by a series of events. The heavy chain
binds a co-receptor complex, the glycoplipid cellular receptor, (GT1b, GD1b, GQ1b or
GD1a), and the protein synaptotagmin II (19, 84, 116, 117, 156, 190). After binding, the
receptor-ligand complex is internalized via endocytosis, the light chain is translocated
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into the cytosol and acts on nerve endings by inhibiting the release of the
neurotransmitter, acetylcholine (68, 84). The continued inhibition of acetylcholine
release causes flaccid paralysis that may eventually lead to respiratory failure if the
paralysis extends to the respiratory muscles (59).
Symptoms begin 18-24 hours after ingestion of the toxin and include double
vision, blurred vision, slurred speech, difficulty swallowing and muscle weakness (53).
The intoxication is characterized by cranial nerve palsies followed by symmetrical
descending flaccid paralysis of motor and autonomic nerves (157, 163). Patients remain
fully alert until death (53, 159). If detected early enough after the ingestion of the toxin,
(usually within the first 24 hours of symptoms appearing), botulism can be treated with
trivalent antitoxin (types A, B and E) which halts the progression of paralysis and
shortens the length of the illness (148, 159). The antitoxin acts by neutralizing any free
toxin in circulation; thereby, inhibiting the toxin from binding to nerve endings (148,
159). In the United States, more than 80% of patients are treated with antitoxin (13). If
the presence of the toxin is detected after the neurotoxin has begun to effect nerve
endings and cause damage, supporative care is given to the patient (13, 53, 148, 159).
Types of botulism. Botulism is commonly acquired through ingestion of toxin in
food that has been improperly prepared prior to its consumption (53, 102, 159).
Foodborne botulism is rare in the United States and is usually associated with homecanned vegetables, fruits and meat products (13, 148, 159). Spores survive in foods that
are incorrectly processed and are only inactivated by heating to 121°C under pressure of
15-20 lb/in2 for at least 20 minutes (159). Toxin production only occurs in an anaerobic
environment with a low salt concentration and a minimum pH of 4.6 (13, 159). Between
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1950 and 1996, the CDC reported 444 cases of foodborne botulism with a case-fatality
ratio of 15.5% (13). A total of 263 cases were reported to the CDC between the years
1990-2000 (159). Of those cases, there was a case-fatality ratio of 4% (159). In 2003, a
total of 8 cases of foodborne botulism were reported to the CDC with a case-fatality ratio
of 25% (15).
Infant botulism is the most common form of botulism in the United States (14, 85,
163). Infant botulism was first recognized in the United States in 1976 when the toxin
and/or cells were detected in the feces of infants (163). This type of botulism is an
infection with spores obtained from contaminated honey (163). The spores temporarily
colonize and germinate in the intestine of the child and produce toxin. It is recommended
that infants who are still nursing should not be given honey (163). Symptoms include
constipation, trouble sucking, swallowing, or crying and progressive muscle weakness
(14). The CDC reports the annual incidence of infant botulism is 2 per 100,000 live
births (13).
Wound botulism results from the colonization of a wound with C. botulinum
(133). When the skin is compromised and contact with contaminated soil or gravel
occurs, the tissue may become infected with C. botulinum. This form of botulism is very
rare and disease results in the production of neurotoxin, which travels through the
bloodstream and to the nerves (133). Symptoms are similar to those associated with
foodborne botulism without the gastrointestinal involvement: blurred vision, sore throat,
trouble swallowing and the eventual culmination in paralysis and death. Wound botulism
was first recognized in 1943 and through 1990, only 47 cases were reported to the CDC
(59, 133). Since 1990, the majority of wound botulism cases have been associated with
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IV drug use (9, 110, 121, 133). Between 1990-2002, 210 of 217 cases reported to the
CDC were associated with IV drug use (133).
Due to the potency of the neurotoxin, botulism is a major threat as a bioweapon
(3). The toxin can be aerosolized and cause the same disease as foodborne botulism
through inhalation. One gram of aerosolized toxin has the potential to kill 1.5 million
people (3, 121). The 1972 Biological and Toxin Weapons Convention prohibited the
offensive development of bioweapons (94); however, Iraq continued to develop their
weapons program (3). Iraq disclosed to the UN Security Council after the Gulf War of
1991 that over 19,000 L of concentrated botulinum toxin had been produced (3, 193). Of
the 19,000 L, 10,000 L had been loaded into military weapons for use (3). Due to the
serious threat botulinum causes as a bioweapon, the CDC continues to monitor any
reported cases.
Detection of Clostridium botulinum and Botulinum Toxin
Botulism is most effectively treated soon after the appearance of symptoms.
Rapid diagnosis is important due to the damage exerted on nerve endings. Currently, the
mouse bioassay is the gold standard for the detection of botulinum toxin or for
differentiation of serotypes (1, 47, 53, 59, 118, 181). Mice are injected with an
intraperitoneal dose of botulinum toxin and observed for a period of four days (4, 47,
181). Animals are observed for symptoms of botulism; those injected with higher doses
show symptoms within 8 hours while those injected with lower doses can take a few days
to develop symptoms (4). The limit of detection for the most active serotype is 10-20
pg/ml (4, 181). The mouse bioassay has several disadvantages: (1) it takes several days
for results; (2) many animals are required for the assay; (3) special facilities are required;
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(4) there are inherent hazards associated with injecting the mice; (5) it is expensive; and
(6) additional testing is required to differentiate neurotoxin serotypes (4, 47, 181).
ELISAs have been developed in lieu of the mouse bioassay for the detection of
the botulinum toxin (4, 47, 59, 181). The ELISA allows for the screening of a larger
sample size with more rapid results without the need for animals. Ferreira et al. reported
a limit of detection of 10 minimal lethal dose (MLD) per ml (47). The current MLD
currently is 0.02 ng for type A toxin (47). Wictome et al. reported a limit of detection of
0.5 MLD per ml when utilizing a colorimetric immunoassay for type B toxin (181).
Signal amplification was used in conjunction with an ELISA by Sharma et al. in several
different types of food matrices including liquids, solids and semi-solids and generated
extremely sensitive limits of detection for toxin types A, B, E, and F (153). The limits of
detection for the four different serogroups were as follows: type A toxin was 60 pg/ml,
type B was 176 pg/ml, type E was 163 pg/ml and type F was 117 pg/ml (153).
The use of affinity molecules other than antibodies in association with botulinum
toxin is also being employed in conjunction with an ELISA. Liposomes containing the
natural cellular receptor for botulinum toxin, (GT1b, GD1b or GQ1b), and fluorophorelabeled lipids have been used as detection molecules in a sandwich fluoroimmunoassay
(156). Concentrations as low as 1nM of botulinum toxin could be detected with
fluorescently labeled liposomes (156). Another receptor immunoassay was developed
with GT1b inserted into a liposome (1). In this assay, botulinum toxin was detected as a
colored band on a nitrocellulose membrane either visually or with a densitometer (1).
The limit of detection for this assay with type A toxin was 15 pg/ml (1). Current ELISA
assays are not sensitive enough to replace the mouse bioassay and make take up to 5 days
28

for the cultures to produce toxin; therefore, they do not produce results in a near-real time
fashion (118). There is a need for a rapid and sensitive test and assays utilizing
molecular techniques and biosensors are being developed as an alternative to the ELISA
and mouse bioassay.
PCR can be used to identify toxin genes in 24 h botulinal cultures as type A, B, E
or F neurotoxin producers (32, 161). PCR uses nucleic acid probes which, under
controlled conditions, hybridize with the complementary nucleic acid sequences of
interest. Clostridium botulinum isolates are enriched anaerobically for 24 hours to obtain
vegetative cells. A simultaneous PCR reaction for all 4 toxin serotypes can then be
performed. The PCR may be used in conjunction with the mouse bioassay as a
confirmatory test (32, 161). This type of PCR assay does not produce real-time results
but merely shortens the time interval with which a diagnosis could be provided. Realtime PCR assays have been developed for the detection of type A, B and E toxins from
purified DNA samples and crude DNA extracted from broths (2). Using real-time PCR,
seven out of eight botulinum cases were identified which provided a faster preliminary
diagnosis than conventional bioassays (2).
A fiber optic-based biosensor assay utilizing a sandwich immunoassay produced a
limit of detection of 5 ng/ml for botulinum toxin type A (118). Immobilized antibodies
were used as a capture molecule and fluorescently labeled antibodies were used as a
detector. The toxin detection occurred in one minute with previously prepared fibers.
The assay provided sensitive results with no cross-reactivity to the similar toxin, tetanus
toxin.
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Immunoassays
Background
Immunoassays have been in use since the 1960s when Rosalyn Yalow and
Solomon Berson used a radioimmunoassay to detect and quantify insulin in plasma
samples (188). These assays combine the principles of biochemistry and immunology,
enabling scientists to detect very low concentrations of a specific antigen. The principle
of the test involves using antibodies as reagents. In an immunoassay, the antibody at a
specific concentration - either a primary or secondary - is attached to a label: an enzyme
(enzyme immunoassay; EIA), a radioisotope (radioimmunoassay; RIA) a fluorescent dye
(fluorescent immunoassay; FIA) or a luminescent label (luminescence immunoassay;
LIA). The conjugation of the antibody to one of these labels provides the means for
determining the concentration of an unknown antigen. Depending on the type of label
conjugated to the antibody, a color change, emission of light, the amount of radioactivity
or some other signal is produced and measured after the immunological binding reaction.
Special visualization systems including spectrophotometer, fluorometer and luminometer
are required to quantitate the amount of label or end product present.
Enzyme immunoassays (EIA) are the most widely used type of immunoassay. A
large number of samples and complex antigens such as bacteria can be assayed using EIA
(139). Sensitivity, the ability to detect low levels of antigen, and specificity, the ability
to differentiate between antigens, are two ways assays can be described. Sensitivity and
specificity are both dependent on the antibody antigen interaction. EIAs are easy to
perform and involve the basic principle of antibody-antigen interaction: typical
interactions are highly sensitive and very specific. Thus, immunoassays are practical
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when an unknown concentration of an antigen needs to be quantified. In a sandwich
assay, an antigen is sandwiched between two antibodies: a capture antibody immobilized
on a solid surface and a detection antibody with a label. In a direct assay, cells or antigen
are adsorbed to wells of a microtitre plate. The method of detection with different assay
formats can be divided into two categories: direct and indirect.
Detection Format
The direct sandwich immunoassay (Figure 6a) uses two layers of antibodies to
detect antigen. Antigen of interest must have at least two antigenic sites: one to bind
capture antibody and one to bind labeled detection antibody. Antibodies are attached to a
solid surface to capture antigen. Labeled primary antibody binds directly to the antigen
and is detected by the label. If the label is an enzyme, such as peroxidase or alkaline
phosphatase, substrate is added and the unknown concentration of the antigen is
determined. If the label is a fluorophore, such as Cyanine 5 or rhodamine, under the
appropriate wavelength of light, it fluoresces and antigen concentration is quantified.

label
Detector antibody
antigen
Capture antibody

FIGURE 6a. Direct detection with sandwich immunoassay.

31

label
Secondary antibody
Primary antibody
antigen

FIGURE 6b. Indirect immunoassay detection with direct adsorption.
Passive adsorption allows ELISA reagents, antibody or antigen, to attach
passively to the solid phase of a surface during an incubation step. In an indirect assay,
antigen binds to capture antibody followed by the addition of primary antibodies (Figure
6b). A binding event occurs between the primary antibodies that have an affinity for the
antigen of interest. The binding of the primary antibody is followed by incubation with
labeled secondary antibodies directed against the species in which the primary antibody
was made. Upon binding of the labeled secondary antibody, antigen concentration is
determined.
Given these two detection formats, it is imperative to have high quality antibodies
with good specificity and an advanced detection system in order to develop a quality
immunoassay.
Antibodies
Immunoglobulins, or antibodies, are a group of secreted glycoproteins found in
the serum of all animals. The production of antibodies occurs at the culmination of a
series of events between B lymphocytes and effector cells of the immune system. When
a mature B cell encounters a specific antigen, it will undergo activation, proliferation and
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differentiation leading to the eventual production of antibodies (139). Antibodies
perform two key functions; they bind antigens and some mediate effector functions
throughout the body: fixation of complement and binding to various cell types (139).
Antibodies are extremely specific thus making them an ideal molecule for the use in
assays to detect a variety of substances.
There are five classes of antibodies, IgG, IgA, IgM, IgD and IgE, determined by
amino acid sequence differences in the constant region of the heavy chain. The
antibodies of the class IgG are the most prevalent antibody in serum and the most
commonly used in immunoassays. IgG antibodies have a molecular weight of
approximately 150 kD and are composed of two light and two heavy chains. B
lymphocytes are capable of making over 18 billion antibodies through a variety of
mechanisms: site-specific recombinations, mutations, random gene splicing, splicing
inaccuracies and class switch recombination (139).
Antibodies need to be specific with a high affinity for the target antigen for use in
immunoassays (97, 134, 166). Affinity is the strength of the bond between the antigen
and antibody. In order to detect antigen in low concentrations, the affinity of the
antibody must be high. The antibodies must be stable and have low cross reactivity with
other molecules. If an antibody has a high degree of cross-reactivity with other
molecules aside from the antigen of interest, then quantitation of the antigen could be
inaccurate. When selecting an antibody for a particular application, it is important to
choose one that provides the greatest amount of sensitivity with the least amount of crossreactivity.
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The antigenic determinant, or epitope, is a single antigenic site to which the
antibody binds. The size of an epitope is normally 6-8 amino acid residues. A single
antigen can have multiple epitopes. In an immune response, if the antigen is large (e.g., a
bacterium), animals will produce a large number of antibodies from different B cells.
Each B cell will produce its own type of antibody. These antibody producing cells
manufacture antibodies that recognize different epitopes on the same foreign molecule.
This heterogeneous mixture of antibodies is found in the serum of animals. The natural
collection of antibodies produced from different B cell lines is called polyclonal
antibodies. Polyclonal antibodies used for research purposes are normally made from
goat, rabbit or sheep (57). Polyclonal antibodies are the most commonly used antibodies
for immunoassays (57). These antibodies remain stable for approximately one year at
4°C when in suitable buffers and held at high protein concentrations of 1 mg/ml (57).
Monoclonal antibodies are produced by only one type of B cell and can recognize
only a single type of epitope on a complex antigen. In 1975, Köhler and Milstein
developed the first hybridomas by fusing together mouse myeloma cells and lymphocytes
from the spleens of mice that had been immunized with a specific antigen (81). The
hybridomas combine the immortality of the myeloma cell with the antibody producing
ability of the lymphocyte.
Monoclonal antibodies are directed against a single epitope and therefore can
function as a capture or detection molecule within the constraints of the same assay.
Monoclonal antibodies generated from the same clone would compete against itself for
the same epitope if it were used as both the capture and detection molecule in the same
immunoassay.
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Labels
In order to detect and quantify an antigen, antibodies must be conjugated to a
label. The presence of labeled directly correlates with the concentration of antigen. The
original label used for immunoassays was the radioisotope (125). Since the development
of the immunoassay, different enzyme labels with a matching substrate or fluorophores
have been used to produce measurable end products. Enzymes used for colorimetric
assays include horseradish peroxidase and alkaline phosphatase. Chromogenic,
flurogenic and chemiluminescent substrates can be used with either enzyme.
Fluorophores, such as rhodamine, can be used as an antibody label. Also, enzymes for
the detection of chemiluminescence (peroxidase-catalyzed luminol assays) are used in
immunoassays. In order to utilize the immunoassay without the constraints of
radioactivity, enzymatic, fluorescent and chemiluminescent labels are replacing
raidioisotopes (125).
Most enzymatic detection systems offer an equal or better detection capability
than the radioactive systems without the dangers associated with radioactivity. When
using an enzymatic tag, samples can be read with a spectrophotometer, luminometer or
fluorometer. In order to get faster and better results, fluorescent and chemiluminescent
systems are employed (125).
Fluorescent labels provide a powerful label in immunoassays. Typically, the
results produced from a fluorescent label are more sensitive and can be obtained quicker
than an enzymatic or colorimetric assay; however, their potential can be limited if dyes
are not stable and there is sample interference (57). Also, a complex and expensive
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instrument for the detection of fluorescence, a fluorometer, is required if a fluorescent
label is chosen.
Chemiluminescent tags are the most sensitive and require the fewest amount of
reagents of the four labels mentioned (89, 106, 189). Unlike colorimetric or fluorescent
assays, samples assayed with chemiluminescent tags contribute little to no inherent
background interference (106).
Regardless of the label and detection system employed, all immunoassays are
based on the same antigen-antibody interactions. Therefore, the specific interaction of
antigen and antibody is very important for low limits of detection-the smallest
concentration measurable with a particular assay-making immunoassays applicable to a
wide variety of compounds of interest. Colorimetric, fluorescent and chemiluminescent
assays are safer and more sensitive than radioimmunoassays and have therefore become
more popular in use and application.
Biosensors
Background
There is an increased demand for detection systems capable of producing
sensitive and specific results within a relatively short period of time. The need for this
type of detection system spans different types of industries: environmental, agricultural,
pharmaceutical, food and public health (87). Biosensors are analytical detection devices
which utilize biological molecules to detect other biomolecules or chemical substances.
All biosensors exploit the ability of biomolecules to specifically recognize a target
analyte, a substance an assay aims to detect. Biosensors combine this specific interaction
or affinity between a biomolecule and its target with signal generation near or directly at
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the surface of a transducer (Figure 7) (30). The transducer takes one type of energy and
converts it to another. After the molecular recognition between biomolecule and analyte
occurs, a signal is produced that can be coupled and converted by the transducer into a
signal that can be measured (30). The signal produced by the transducer, (e.g.
electrochemical, optical or thermal), corresponds to the concentration of the target (30).
Biosensors have existed since the 1970s but the interest in developing sensors for near
real-time/real-time detection has lead to advances in their development (186). Different
types of affinity systems can be used in conjunction with a biosensor, including the
following: enzyme-substrate, antibody-antigen, receptor-ligand, lectin-sugar or nucleic
acid for complementary sequence hybridization (30).

Enzyme
Antibody
Receptor
Lectin
Nucleic
acid

Electroactive
substance

Electrode

pH change

semiconductor
pH electrode

Light

Photon counter

Mass change

Biological
Recognition
Element

Electric signal

Pizoelectric device

Signal Transducers

FIGURE 7. General principles of a biosensor (138).

Immunoassays are frequently used in conjunction with biosensors. As described
previously, antibodies are most commonly used; however, other biomolecules are also
used to recognize and bind target. These biomolecules can be immobilized to the solid
surface platform through passive adsorbption, linked through a biotin-streptavidin bridge
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or covalently attached to serve as capture molecules (154). A detection molecule, which
also recognizes the target, is tagged with an appropriate label and is used to generate a
measurable signal (92). Biosensors are not without their disadvantages: some are
expensive, produce inconsistent results or are bulky and not practical for in the field use.
However, biosensors offer several advantages over conventional laboratory techniques.
Biosensor assays are generally easier to perform and do not require trained personnel
(92). For example, home pregnancy tests and glucose monitoring systems are bioassays.
A home pregnancy test utilizes monoclonal antibodies directed against HCG to produce a
colorimetric change. The over the counter home pregnancy test is a notable example of
an effective biosensor: it is inexpensive, disposable, simple and accurate. Due to the
specific recognition required between biomolecule and analyte, biosensors generate high
degrees of sensitivity and specificity. Near real-time/real-time detection in complex
matrices is also an advantage frequently derived from the use of a biosensor (37, 38, 39,
92). Finally, fully automated biosensor assays that can operate unattended have the
potential to be integrated into on-line monitoring systems in water treatment plants or
food processing facilities.
Types of Optical Biosensors
Optical biosensors utilize optical grade glass, plastic or silicon fiber to transmit
light from one position to another. Light is propagated through the interior core of the
fiber and reacts with reagents that are placed near the surface of the fiber. The light
emission is converted into a quantifiable signal and the intensity correlates with the
concentration of the unknown target. The transducer (a monochromator, lenses and
photomultiplier tube) receives a signal and collectively converts it into an electrical signal
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that can be recorded (87). Types of optical biosensors include surface plasmon resonance,
fiber optic and evanescent wave.
Evanescent wave Fiber-Optic Biosensor
One type of optical biosensor is based on evanescent wave technology. An
evanescent wave fiber-optic biosensor uses the principle of total internal light reflection
(Figure 8). Electromagnetic waves of light are propagated within the waveguide and a
portion of it travels outside the core and is referred to as an evanescent wave. When
biomolecules labeled with fluorophores fall within the range of the evanescent wave
(approximately 100-1000 nm), the fluorophores become excited by the light source and
the fluorescent signal is coupled back through the fiber. A photodiode allows for
quantitation of the light emitted from the fluourophores within the range of the
evanescent wave.
One type of fiber-optic evanescent wave biosensor detection system is the
Analyte 2000 (Research International, Monroe, WA), which uses an optical fiber as the
waveguide (37, 38, 39, 43, 85, 86, 91, 92, 155, 170, 171). The Analyte 2000 utilizes a
sandwich immunoassay based on the specificity of antigen-antibody or receptor-ligand
binding. An immobilized, capture biomolecule is attached to a fiber-optic waveguide
through a streptavidin-biotin bridge or passively adsorbed. This waveguide is exposed to
a substance containing the suspect antigen and then subsequently exposed to a detection
biomolecule conjugated to a fluorophore. Excitation light from a 635 nm laser diode is
propagated through the waveguide and fluorescent molecules within approximately 100
nm of the fiber are excited (92, 178). The emission light from the excited fluorophore
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reverberates into the waveguide and is quantitated in picoamps and displayed on a
computer.
Evanescent wave
travels outside the core

Light guided in core

FIGURE 8. Total internal reflection in optical fiber (154). The propagation of
electromagnetic waves in optical fiber by total internal reflection. A portion of the light
travels just outside the core, approximately 100 nm, and is referred to as the evanescent
wave or field.

Affinity-Based Elements
There are a wide variety of biomolecules that can function as capture and/or
detection molecules in conjunction with biosensors including antibodies, receptors or
nucleic acids (70). When selecting an affinity-based recognition element for use with the
biosensor, it is important to consider the application of the assay. The biomolecule
should be selected based on its ability to minimize non-specific binding and increase
specificity and sensitivity (70, 162). Antibodies, either monoclonal or polyclonal, are the
most commonly used recognition molecule in conjunction with biosensor assays (70, 97).
Theoretically, polyclonal antibodies would not compete for the same epitope and could
be used as both a capture and a detection molecule. Monoclonal antibodies from the
same clone would theoretically compete for the same epitope if used as a capture and
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detection molecule. Therefore, it would seem advantageous to use polyclonal antibodies
as both detection and capture molecule or a combination of polyclonal and monoclonal
antibodies.
The receptor/ligand relationship offers an alternative to antibodies in developing
biosensor assays (162). Receptors are cell surface molecules, either cytoplasmic proteins
(steroid receptors) or transmembrane receptors (gangliosides), which exhibit specificity
for a particular effector molecule (105, 135, 143, 174). As in antibody interactions,
receptors may bind their respective ligands with low or high affinities. High affinity
interactions are desirable in biosensor assays. Ganglioside receptors are
glycosphingolipids widely distributed in all tissues but heavily concentrated in the central
nervous system of animals (105, 174). Gangliosides are natural cellular receptors for
toxins and like antibodies, rely on specific interactions with ligands. Common
gangliosides include GD1a, GD1b, GD2, GD3, GM1, GM2, GM3 and GT1b (82). Viral
and bacterial pathogens exploit the natural relationship between ganglioside/ligand
interactions to gain entry into host cells (105, 143, 164, 174). Binding of these pathogens
to ganglioside receptors can be utilized for detection. Gangliosides can be used as
capture molecules when immobilized on solid surface assay platforms or labeled with a
tag and used as a detection element (105, 143, 162, 165, 174).
Another non-antibody based biological interaction used with biosensor assay
development is the nucleic acid probe that can specifically hybridize with its
complementary sequence. A nucleic acid probe is a segment of DNA designed
specifically to a nucleic acid target. Unlike antibodies or receptors, nucleic acid
recognition elements can only bind and interact with molecules containing RNA or DNA.
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These probes lack the ability to detect proteins, chemicals or other biological molecules.
Recognition of the target nucleic acid is dependent on the formation of stable hydrogen
bonds between the complementary nucleic acid probe and its target (70). Nucleic acid
probes can be used for either capture or detection.
Antibodies, receptors and nucleic acid probes, can be used in a variety of assay
formats. One type of element may be used as both the capture and detection molecule or
a combination of recognition molecules can be used in unison with one another. Using
more than one type of element per assay could limit the amount of competition that
occurs for binding sites as long as the two elements do not bind to the same epitope. If,
in the same assay, a ganglioside and an antibody are used together as capture and
detection molecule, respectively, than theoretically they are not competing against one
another for the same recognition site. This type of assay could then potentially increase
the specificity of the assay due to the double recognition of the target analyte.
Summary
Millions have suffered and thousands have died from the virulent toxin released
from the cells of V. cholerae. Cholera is transmitted through the fecal-oral route and
there is a higher incidence of infection and endemnicity in areas with poor sanitation.
The cells of V. cholerae are best adapted to marine and brackish waters and exist in either
a commensal or symbiotic role with marine organisms. Cholera occurs most often in
populations with low socioeconomic status: sanitation facilities are poor or nonexistent,
personal hygiene practices are wanting and the people lack the education to understand
the disease. Eradication of the disease may be too big of a task for national or
international control programs. However, measures can be taken for quick detection
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followed by containment of the disease. The most critical element of cholera control
during an epidemic is the early identification of the illness, proper notification of health
officials, adequate healthcare facilities and the disposal of raw sewage (7).
The neurotoxin produced by C. botulinum is one of the most lethal biological
toxins known. Botulism is rarely seen manifested in society; however, it is possible to
suffer lethal food poisoning with improperly processed foods. Recent world events have
focused the world’s attention and raised awareness to the potential use of this toxin as a
biological agent against our military and civilian populations. Botulinum toxin is
relatively easy to obtain or produce and the intentional contamination of food or water
supplies remains a viable threat.
The purpose of this research was to develop a sensitive and specific assay
utilizing gangliosides in conjunction with the fiber-optic evanescent wave biosensor to
detect biological toxins. The biosensor immunoassay is a detection system that has the
capability to produce rapid, sensitive and specific results in near real-time. Gangliosides,
recognition elements other than antibodies, were used as capture or detection molecules.
Assay development was performed using CT as the model protein. Once a rapid,
sensitive and specific assay was developed to detect CT in buffer using the biosensor, the
method was applied to the detection of the toxin in oysters. Shellfish, specifically oysters
when ingested raw or undercooked, have been implicated in the transmission of cholera
(40, 109, 122, 123).
The pathogenicity of cholera is directly related to the production of CT. A rapid,
sensitive and specific assay is necessary for the detection of CT in contaminated water
and food. The majority of assays used to assess contamination of food and water with V.
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cholerae rely on conventional laboratory techniques: enrichment, isolation, serological
and/or biochemical tests. The presence of CT genes can be detected through PCR;
however, enrichment is often needed and the assay fails to determine if the protein is
being expressed. Vibrio cholerae cells recovered from contaminated food or water can be
induced in vitro to produce CT. This type of assay can assess the virulence of the strain
but is time consuming. Enrichment followed by inoculation into induction media is
needed to induce the organism to produce the CT. For these reasons, utilizing the
evanescent wave, fiber-optic biosensor is an innovative means of detecting CT directly
from matrices.
After the CT biosensor immunoassay was developed in combination with
gangliosides, the protocol was used in assay development for the detection of botulinum
toxin. The mouse assay is the accepted standard for the detection of botulinum toxin.
This assay requires the use of many animals, and requires several days to determine the
amount and type of toxin present (1, 47, 53, 59, 118, 181). Due to the potency of the
botulinum neurotoxins, it is important to rapidly detect and differentiate between the
toxins in food, clinical or environmental samples. A rapid, sensitive and specific assay is
needed for the detection and differentiation of botulinum neurotoxins.
The ability to rapidly and accurately detect contaminated food and water would
serve as a preventive measure and aid those involved in public health, quality control
specialists and possibly first responders in the reduction of the spread of disease.
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MATERIALS AND METHODS
Bacterial strains
Vibrio cholerae Pacini 569B ATCC 25870 and Vibrio cholerae Pacini El Tor
ATCC 39050 were obtained from the American Type Culture Collection (Manassas,
VA). Vibrio cholerae O1 El Tor Inaba was obtained from the Centers for Disease
Control and Prevention (CDC, Atlanta, GA). Bacteria were suspended in tryptic soy
broth with 20% glycerol (Remel, Lenexa, KA) and stored in a -80°C freezer until needed.
Media and Culture Conditions
Stock cultures. All cultures were grown on tryptic soy agar plates (TSA, Remel)
for 18 hours in a 37°C incubator and serially diluted in 0.01 M phosphate-buffered saline,
0.85% NaCl, pH 7.4 (PBS) for use in assays.
Enrichment and selective media. Alkaline peptone broth (1% NaCl, 1% peptone ,
pH 8.5) was used for the enrichment of all V. cholerae isolates from seawater and oyster
matrices. Casamino acids yeast extract medium (CAYE, 3% casamino acids, 0.3% yeast
extract, 0.05% K2HPO4, pH 7.0, CAYE with 0.2% glucose, Instant Ocean (Aquarium
Systems, Inc. Mentor, OH.), Salt water culture medium (0.05 % peptone, 0.03 % yeast
extract, 0.03 % glycerol, 0.01 % CaCO3), Salt water culture medium with 0.2% glucose,
Salt water culture medium made in Instant Ocean and Salt water culture medium with
0.2% glucose made in Instant Ocean were used in the development of enrichment assays
(108).
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Thiosulfate Citrate Bile Salts agar (TCBS, Becton Dickinson & Co., Sparks, MD)
was used for the selective plating of V. cholerae. Plates were grown at 37° C in an
incubator for 18 hours. Suspect yellow colonies were tested using API 20E (Biomerieux,
Durham, NC) and PCR for confirmation.
Toxins
Lyophilized cholera toxin beta subunit (CT-B) and cholera toxin (CT) were
purchased from Sigma Chemical Co. (Saint Louis, MO) and reconstituted in 0.1M
phosphate buffered saline, pH 7.4. Two botulinum toxoids were provided by the CDC.
Type-A botulinal toxoid was at a 1:10,000 dilution and type-B botulinal toxoid at a
1:1,000 dilution.
Gangliosides
The lyophilized gangliosides GM1, GD1b and GT1b were purchased from Sigma
Chemical Co. The GM1 was reconstituted in PBS.
Liposomes
Liposomes were made to specification by Dr. Anup Singh at the Sandia National
Laboratories (Livermore, CA). The liposomes (Figure 9) were composed of L-αdistearroylphosphatidylcholine (DSPC), cholesterol, Alexa-DHPE (Alexafluor 647-1,2dihexadecanoyl-sn –glycerol-3-phospoethanolamine, Molecular Probes, Eugene, Oregon)
and GT1b (Sigma Chemical Co.) (151). The mole ratio used was 42.5:42.5:10:5
(DSPC/cholesterol/Alexa Fluor/GT1b) (156).
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FIGURE 9. Liposome construct (156).

Antibodies and Labeling
Sources. Lyophilized rabbit anti-cholera toxin beta subunit antibody was
purchased from Biogenesis (Kingston, NH) and reconstituted in PBS. Lyophilized rabbit
anti-V. cholerae antibody was purchased from Difco (Sparks, MD). Lyophilized rabbit
anti-botulinum toxin antibody was purchased from Accurate Chemical and Scientific
Corporation (Westbury, NY) and reconstituted in PBS. Goat anti-botulinum type A,
rabbit anti-botulinum type B and goat anti-botulinum type B antibodies were a gift from
the CDC. Affinity purified peroxidase goat anti-rabbit IgG was purchased from
Kirkegaard & Perry Laboratories Inc. (KPL, Gaithersburg, MD). Goat anti-rabbit IgG
conjugated to alkaline phosphatase was purchased from Sigma Chemical Co. Affinity
purified peroxidase rabbit anti-goat IgG was purchased from Jackson Immunologicals
(West Grove, PA).
Cyanine 5 labeling. Cholera toxin and botulinum toxin antibodies were labeled
directly with the cyanine 5 fluorophore (FluoroLink Cy5 Reactive Dye 5-pack Amersham
Biosciences, Piscataway, NJ). Labeling was performed according to the protocol
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described previously by Demarco et al. (37). The antibody to be conjugated was diluted
to 1mg/ml in 500 µl of conjugation buffer (0.1 M carbonate-bicarbonate buffer, pH 9.3).
The antibody solution was added to the cyanine 5 dye pack vial. The dye pack vial was
placed in the original foil packaging and placed at 4°C for 18 hours. Free dye and labeled
antibody were separated by filtration on a Bio-Gel P10 column (exclusion limit of 1,500
to 20,000 Da; Bio-Rad, Hercules, CA). A 10 ml bed volume was poured and equilibrated
with PBS-0.1% sodium azide. Labeled-antibody fractions were collected and the molar
concentration of the labeled antibody was determined using a DU®-64 spectrophotometer
(Beckman, Fullerton, CA) set at 280 nm and 650 nm. Cy5 labeled antibodies were stored
at 4°C until needed.
Biotin labeling. Antibodies were labeled with biotin using succinimidyl-6(biotinamido) hexanoate (EZ-Link NHS-LC-Biotin; Pierce, Rockford, IL). Labeling was
performed according to the protocol described previously by DeMarco et al. (37). One
mg of EZ-Link NHS-LC-Biotin was dissolved in 1 ml of N,N-dimethylformamide
(DMF); 75 µl of this solution was added to 425 µl of antibody that had been dissolved in
0.1 M sodium carbonate, pH 8.5, at a concentration of 2 mg/ml. The solution was then
placed on ice for 2 hours. Free biotin and labeled antibody were separated by filtration
on a Bio-Gel P10 column. Labeled-antibody fractions were collected in half ml fractions
and the protein concentration of the labeled antibody was determined using a DU®-64
spectrophotometer set at 280 nm. Biotinylated labeled antibodies were stored at 4°C
until needed.
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Viable Counts
Cells were resuspended in 0.1 M PBS, pH 7.4 (100 dilution). Ten-fold serial
dilutions were made, 10-1 to 10-7. Nine hundred micrliters of sterile PBS, pH 7.4, in
sterile microfuge tubes was used as the diluent. One-hundred microliters of appropriate
dilutions (usually 10-5, 10-6, 10-7) were duplicate plated onto TSA and incubated at 37°C
for 18 hours.
Oysters
Unshelled oysters processed by Hilton’s Willapoint (South Bend, WA) were
purchased from Publix (Lakeland, FL). Live oysters were harvested from the northwest
side of the Gandy Bridge at Tampa Bay, Fl. (Figure 10). Live oysters were collected and
immediately placed on ice. They were transported back to the laboratory within an hour
and placed in a 10 gallon tank containing Instant Ocean (20 ppt NaCl) as described by
Murphree and Tamplin (111).
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FIGURE 10. Map of Tampa Bay, Florida. Live oysters were harvested during low tide
from the northwest side of the Gandy Bridge on the St. Petersburg side of the Tampa
Bay.
Toxin Assays
Bicinchoninic acid protein assay. Fifty parts of BCA reagent A (Sigma
Chemical Co.) were mixed with 1 part BCA reagent B (Sigma Chemical Co.) to make the
working reagent. A standard curve was made using Bovine Serum Albumum (BSA,
Fisher, Pittsburgh, PA). For each concentration, BSA was mixed with PBS to a final
volume of 50 µl. One ml of the working reagent was added to each BSA concentration
and incubated at room temperature for 1 hour. At the same time CT-β was serially
diluted and then one ml of working reagent was added and incubated at room temperature
for 1 hour. The absorptions were determined using a DU®-64 spectrophotometer set at
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562nm. The concentration of the protein was determined by extrapolating from the
standard curve line.
SDS-PAGE. 12% Bis Tris precast gels purchased from Invitrogen (Carlsbad, CA)
were used. Twenty microliters of the protein sample, 10 µl of sample buffer (Invitrogen,
Carlsbad, CA), 4 µl of reducing agent (Invitrogen) and 6 µl of DI water were mixed and
heated at 70°C for 10 minutes. Twenty microliters of each protein sample mixture was
used per well. One well contained 10 µl of the Novex Color Marker 12 (Sigma Chemical
Co.). MES-DES running buffer (Invitrogen) was used and the gel was electrophoresed at
200V for 40 minutes. The gel was then stained with Coomassie Blue R250 (Sigma
Chemical Co.) for one hour. The gel was destained with a 7.5% methanol, 10% acetic
acid solution for 30 minutes and then placed in DI water for 18 hours.
Western blot. An SDS-PAGE gel was removed from the gel box and transferred
to a nitrocellulose membrane at 14V, 4° for 18 hours using Towbin buffer, pH 8.3 (173).
The membrane was removed and incubated on a shaker with 5% skim milk/PBS, pH 7.4,
containing 0.1% Tween 20 (PBST, pH 7.4) at 24°C for 10 minutes. The gel was rinsed
once with PBST and then incubated with the primary antibody, polyclonal anti-CT-β
rabbit (Biogenesis) at a 1:500 dilution for one hour at 24°C. This was followed by three
45 second washes with 10 mM EDTA/PBS (pH 8.5). The membrane was rinsed three
times with PBST for 20 seconds each and then incubated with the secondary antibody,
goat anti-rabbit IgG conjugated to alkaline phosphatase at a 1:5,000 dilution for an hour
at 24°C. This was followed by three 30 second washed with PBST. Substrate (50 ml
borate buffer, ph 9.7, 13 mg o-dianisidine, 13 mg β-napthyl acid phosphate) was added
and the membrane was kept in the dark until bands appeared.
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Ganglioside-based ELISA. All volumes were at 100 µl and all incubations were
at 24°C unless otherwise noted. Ganglioside was dissolved in PBS at a concentration of
1.5 µg/ml. One hundred microliters were added to the wells of a 96-well Nunc Maxi
Sorp microtitre plate and incubated at 37°C for 18 hours. This mixture was aspirated and
wells were washed once with PBST. Blocking buffer (PBS, 2 mg/ml casein, 2 mg/ml
BSA) was added and incubated at 24°C for 30 minutes. This mixture was aspirated and
wells were washed once with PBST. The antigens were added into their respective wells
and incubated for 10 minutes. This solution was aspirated and wells were washed three
times with PBST. Polyclonal antibody at a concentration of 10 µg/ml was added to each
well and incubated for 30 minutes. This mixture was aspirated and wells were washed
three times with PBST. Horseradish peroxidase-labeled secondary antibody, anti-rabbit
IgG or anti-goat IgG (KPL) was added to each well at a 1:500 dilution and incubated for
30 minutes. This mixture was aspirated and wells were washed three times with PBST.
QuantaBlue substrate (Pierce Biotechnology, Rockford, IL) was added and incubated for
25 minutes. QuantaBlue stop solution (Pierce Biotechnology) was added and the relative
fluorescence was determined at 325 nm excitation and 420 nm emission with a Spectra
Max Gemini XS fluorometer (Molecular Devices, Sunnyvale, CA). A signal to noise
ratio of 2 was positive detection.
Indirect ELISA. All volumes were at 100 µl and all incubations were at 24°C
unless otherwise noted. Serial dilutions of protein were made in sterile 0.01 M PBS with
0.1% BSA, pH 7.4. Protein was added to the wells of a 96-well Nunc Maxi Sorp
microtitre plate and incubated at 4°C for 18 hours. This mixture was aspirated and wells
were washed once with PBST. Blocking buffer was added and incubated at 24°C for 30
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minutes. This solution was aspirated and wells were washed once with PBST. Primary
antibody at 10 µg/ml was added to each well and incubated for 30 minutes. This mixture
was aspirated and wells were washed three times with PBST. Horseradish peroxidaselabeled secondary antibody, anti-rabbit IgG or anti-goat IgG was added to each well at a
1:500 dilution and incubated for 30 min. This mixture was aspirated and wells were
washed three times with PBST. After washing, QuantaBlue substrate (Pierce
Biotechnology) was added and incubated for 25 minutes. QuantaBlue stop solution
(Pierce Biotechnology) was added and the relative fluorescence was determined at 325
nm excitation and 420 nm emission with a Spectra Max Gemini XS fluorometer
(Molecular Devices). A signal to noise ratio of 2 was positive detection.
Toxin induction. Vibrio cholerae O1 569B ATCC 25870, Vibrio cholerae O1 El
Tor ATCC 39050 and Vibrio cholerae O1 El Tor CDC were grown on TSA. Strains
were induced to produce CT by following the protocol of Minami et al. (108). Ten ml of
modified CAYE broth were placed into sterile 100 mm petri dishes. Each dish was
inoculated with two colonies from each strain. After stationary incubation for 18 hours at
30°C, a loopful of the culture was transferred to a new petri dish containing 10 ml of the
modified CAYE medium with 0.2% glucose. Salt water culture medium, Salt water
culture medium made in Instant Ocean (Aquarium Systems) and CAYE made in Instant
Ocean were also used as enrichment media for the production of CT. This culture was
incubated under stationary conditions for 18 hours at 30°C. Five ml of each culture was
stored at 4°C and 5 ml was centrifuged (1,600 × g, 30 min, 4°C). The supernatant fluids
were filtered through sterile 0.22 µm-pore-size membrane filters. CT in the filtered
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supernatant fluid was detected using the Analyte 2000 (Research International) and an
ELISA.
Toxin spiked oysters. Four grams of oyster (Hilton’s Willapoint, South Bend,
WA) and 36 ml of Alkaline Peptone Water (APW, pH 8.5) were added into a 50 ml
conical tube and spiked with CT (168). The sample was homogenated for 90 seconds at
the highest speed using a PowerGen 125 homogenizer (Fisher) allowed to settle at 24°C
for 15 minutes and then separated by filtration on a Bio-Gel P10 column. A 4 ml bed
volume was poured and equilibrated with PBS with 0.1% sodium azide. Ten oyster
fractions were collected in 500 ul volumes. The CT was detected using the Analyte 2000
(Research International) and an ELISA.
Tank inoculation. A 10 gallon aquarium tank with 10 L of medium was set up
and the liquid was recirculated with an AquaClear aquarium pump (Wal-Mart) (Figure
11). The temperature in the tank was maintained at varying temperatures with a VisiTherm Automatic Aquarium Heater (Wal-Mart). On day one, oysters harvested from the
Tampa Bay were introduced into the tank and allowed to sit for 24 hours, these were
designated the control oysters, tc. On day two, the tank was inoculated with V. cholerae
569B ATCC 25870 to a final concentration of 104 cfu/ml and the oysters collected prior
to inoculation were designated t0. Beginning on day two, oyster and broth medium
samples were collected at the following time intervals: t0, t6, t12, t24, t48 and t72 hours.
Following the method of Murphree and Tamplin, ten oysters from each tank were
scrubbed and their meat pooled (111). The meat was homogenized 1:1 in PBS followed
by serial dilution in PBS. A five tube MPN was prepared by enriching dilutions of oyster
homogenate or tank medium in APW (pH 8.5) at 42°C for 6 hours in a water bath. Each
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tube in the MPN series was then streaked onto TCBS (Difco) (41). Plates were incubated
at 37° C for 18 hours. Suspect V. cholerae isolates were confirmed using API 20E and
PCR.

FIGURE 11. Tank set-up.

API 20E Identification
Yellow colonies that were 2-3 mm in diameter, gram negative rods and oxidase
positive were resuspended in PBS and identified using the API 20E (Biomerieux,
Durham, NC). Colonies identified as V. cholerae were further confirmed using PCR.
PCR
PCR targeted two genes for the identification of Vibrio cholerae: the 564 base
pair region of the cholera toxin A subunit (ctxA) and the 300 base pair region of the 16S23S rRNA intergenic spacer region (its). Primers were made by IDT (Coralville, IA) and
their sequences are listed in Table 5. The forward and reverse primers were diluted to a
10 µm concentration. Each 50 µl reaction volume contained the following: 1X PCR
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TABLE 5. PCR primers for identification of Vibrio cholerae.
Target

Sequence

ctxA

F 5’ CGG GCA GAT TCT AGA CCT CCT G 3’ 564
R 5’ CGA TGA TCT TGG AGC ATT CCC AC 3’
F 5’ TTA AGC ATT TTC TCT GAG AAT G 3’
300
R 5’ AGT CAC TTA ACC ATA CAA CCC G 3’

its

Amplicon
size (bp)

Reference

48
21

buffer, 200 µM each of dNTP mixture, 0.25 µM of the forward and reverse primer, 2 µl
of whole V. cholerae cells resuspended in sterile DI water, 2.5U of TaKaRa ExTaq
polymerase (TaKaRa, Shuzo, Otsu, Japan) and 37.25 µl sterile water. Samples were run
on a Bio-Rad iCycler (Hercules, CA) with the following conditions: 95° C for 2 minutes;
30 cycles of 95°C for 1 minute, 58°C for 1 minute, and 72°C for 2 minute; and extension
at 72°C for 10 minutes. PCR products were visualized by 1% agarose (Amresco Inc.,
Solon, OH) gel electrophoresis. The volume per lane was 8 µl of each PCR reaction
mixed with 2µl of loading dye (Bio-Rad, Hercules, CA). Five microliters of each
PCR/dye mixture was electrophoresed on a 1.5 % agarose gel. A 1 kb PCR marker
(Promega, Madison, WI) was used. Amplicon bands were visualized using GelStar
nucleic acid stain (BioWhittaker Molecular Applications, Rockland, MD) at a
concentration of 3 µl stain/100 ml agarose in TBE buffer and a transilluminator.
Ganglioside-Based Biosensor Assay for the Detection of Cholera Toxin
Analyte 2000 biosensor. The Analyte 2000 (Research International) is a fiberoptic biosensor that utilizes the properties of an evanescent wave in conjunction with a
fluoroimmunoassays to detect a wide variety of molecules (Figure 12). Utilizing four
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different fiber-optic probes and a single wavelength, the Analyte 2000 can analyze up to
four channels simultaneously. Results are produced in near real-time, approximately 20
minutes with previously prepared waveguides. The Analyte 2000 can assay for target
analyte in dirty matrices (37, 38, 39, 86, 171).

FIGURE 12. Analyte 2000 evanescent wave, fiber-optic biosensor.

Fiber preparation. A polystyrene waveguide (Research International) was
sonicated for 30 seconds in isopropanol. The waveguide was rinsed in DI water and
black ink was placed on the distal end of the waveguide to prevent the escape of light.
After the paint dried, the waveguide was added to a glass capillary tube to form a reaction
chamber. The waveguide was incubated with 1.5 µg/ml of GM1 in PBS and incubated
18 h at 37°C. The waveguide was removed from the glass capillary tube and placed into
an Analyte 2000 cuvette as shown in Figure 13. The waveguide was rinsed with 1 ml of
PBST.
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Cuvette
Assay Chamber

Waveguide

Cuvette Cap

FIGURE 13. Assembly of Analyte 2000 cuvette and polystyrene waveguide used in
biosensor assays.

Background readings. Waveguides were rinsed with 1 ml PBST, and then three
background readings were taken by repeating the following steps: each waveguide was
incubated for 5 minutes with 200 µl Cy-5 labeled anti-CT- β-subunit IgG (10 µg/ml) in
blocking buffer (2mg/ml casein, 2 mg/ml BSA in PBS), followed two 1 ml PBST rinses.
The laser was turned on and the value, in picoAmperes (pA), was recorded after the final
rinse. For each reading, the value recorded after the last PBST rinse was designated the
baseline reading. The pA value for each baseline reading was subtracted from the
subsequent baseline reading, and this calculated value was designated as the change in
previous signal for baseline readings 2-4. The average of change in previous signal for
the baseline readings was calculated. The detection limit was calculated as three times the
standard deviation (SD) of the change in previous signal for the baseline readings plus the
average of change in previous signal. When samples were tested, each previous sample
reading was subtracted from the next sample reading.
Sample assay. Figure 14 illustrates the immunoassay used with the Analyte 2000.
Assays were performed by adding 1 ml of sample to the reaction chamber containing the
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fiber waveguide and incubating at 24°C for 10 minutes. The sample was rinsed with 1 ml
PBST and the waveguide was incubated for 5 minutes at 24°C with 200 µl Cy5 anti-CTB-subunit IgG in blocking buffer. The waveguide was rinsed twice with PBST and the
laser was turned on. The signal was recorded in pA. The change in signal (∆pA) was
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binds to analyte and
fluoresces
when laser turned on

FIGURE 14. Illustration of sandwich immunoassay utilized with Analyte 2000. The
target antigen is captured by a bound biomolecule in a standard immunoassay. The
captured antigen is detected by a Cy5-labeled detection antibody.
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calculated as the value of the sample reading after the second rinse minus the value of the
previous sample reading. In order to account for variation among each waveguide, the
values were normalized by using the following equation (85).
∆pA value for sample being tested × 100
∆pA value for 100 ng/ml CT
A sample was considered positive if the change in signal (∆pA) was above the limit of
detection and the normalized value was above zero. A standard curve was generated
using known CT concentrations. CT concentrations of the samples were determined by
extrapolation from the CT standard curve.
The assay for signal amplification follows the same biosensor protocol with the
following exception. The secondary antibody, Cy5 conjugated anti-rabbit IgG, was
incubated with the primary antibody, anti-CT antibody, in a 1:2 ratio, respectively, to a
final protein concentration of 10 µg/ml. The antibodies were incubated at 24°C for 5 min
before incubation on the waveguide.
Cholera toxin standard preparation. The stock solution was prepared by diluting
CT to 100 ng/ml in PBS containing 0.1% BSA. This was serially diluted tenfold in PBSBSA 0.1 %.
Liposome-Based Biosensor Assay for the Detection of Botulinum Toxin
Fiber preparation. Waveguides were prepared as previously described. The
waveguide was incubated in the glass capillary reaction chamber with 100 µl of 100
µg/ml streptavidin solution prepared in PBS for 18 hours at 4°C. The waveguide was
removed from the glass capillary tube and placed into an Analyte 2000 cuvette as shown
in Figure 13. The waveguide was rinsed with 5 ml PBST to remove any unbound
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streptavidin. One hundred microliters of 100 µg/ml of biotinylated polyclonal antibotulinum toxin was prepared in PBS and this was incubated on the waveguide for one
hour at 24°C. Following incubation with the biotinylated antibody, the waveguide was
rinsed with 1 ml of PBST.
Background readings. Fibers were rinsed with 1 ml PBST, and then three
background readings were taken by repeating the following steps: each waveguide was
incubated for 5 minutes at 24°C with 200 µl of liposome at varying dilutions followed
two 1 ml PBST rinses. The laser was turned on and the value, in picoAmperes (pA), was
recorded after the final rinse. For each reading, the value recorded after the last rinse was
the baseline reading. The standard deviation was calculated as previously described.
Sample assay. Assays were performed by adding 1 ml of sample to the reaction
chamber containing the fiber waveguide and incubating at 24°C for 10 minutes. The
sample was rinsed with 1 ml PBST and the waveguide was incubated with 200 µl of
liposome for 5 minutes at 24°C. The waveguide was rinsed twice with PBST. The laser
was turned on and the signal was recorded in pA. The change in signal was calculated as
previously described. A sample was considered positive if the change in signal was
above the limit of detection and the normalized value was above zero.
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RESULTS
Biosensor Immunoassay Development for the Detection of Cholera Toxin
Cholera Toxin Purity
CT-B and CT purchased from Sigma were assayed for the presence of other
proteins. An SDS-PAGE (Figure 15) and a Western blot (Figure 16) were performed to
assess protein purity. The cholera toxin is composed of two subunits with molecular
weights of 27.2 kD A subunit and 11.6 kD B subunit. CT-B is a polymerized form of the
B subunit that, when subjected to the reducing conditions of an SDS-PAGE, should
dissociate into CT-β momomers. CT- β monomers produced a band at approximately
11.5 kD corresponding to the molecular weight of the B subunit. There were no visible
band on either the SDS-PAGE or the Western blot that correlated to the molecular weight
of subunit A. The holotoxin has an A to B ratio of 1:5 and, therefore, it is possible that
there was a smaller concentration of the A subunit. The polyclonal anti-CT-B antibody
used for the Western would not detect the A subunit. The holotoxin dissociated when
subjected to the reducing agent used in the SDS-PAGE. Therefore, the presence of a
band with approximately the same molecular weight corresponding to the B subunit, 11.5
kD, on both the gel and membrane (Figure 15 and 16) and the lack of any other protein
bands reaffirmed that the commercially purchased toxins were not contaminated.
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FIGURE 15. SDS-PAGE of CT and CT-B. Lane 1, 10 ng CT; Lane 2, 10 ng CT-B; Lane
3, marker. The bands visible in lanes 1 and 2 corresponded to the molecular weight of
CT- B.
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Predicted 11.5 kD
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FIGURE 16. Western blot of CT and CT- B. Lane 1, 10 ng CT; Lane 2, 10 ng CT- B;
Lane 3, marker. Filter was probed with anti-CT- B antibody.
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BCA protein assay. A BCA protein assay was done in order to determine if the
concentration of the CT- B protein listed on the Sigma label was accurate (Table 6). The
concentration of the protein was listed at 1 mg/ml.

TABLE 6. Extrapolated CT-B concentrations from BCA standard curve.
Protein concentration

Absorbance @ 562 nm

Extrapolated concentration

0
0.165
0.366
0.513
0.655
0.780
0.188
0.443

-

0 mg/ml BSA
0.2 mg/ml BSA
0.4 mg/ml BSA
0.6 mg/ml BSA
0.8 mg/ml BSA
1 mg/ml BSA
0.2 mg/ml CT-B
0.6 mg/ml CT-B

0.216 mg/ml CT-B
0.538 mg/ml CT-B

The correlation coefficient (r) of the line was 0.997. It was determined that
dilutions made from this commercial source of protein would correspond with the
expected calculated value of that dilution. The label concentration of protein in Sigma
CT- B was considered accurate.
Comparison of Affinity and Specificity of GM1 and Polyclonal Antibody Binding to V.
cholerae Whole Cells and Toxin
A sandwich ELISA using GM1 for capture and anti-CT- B for detection was used
to test the affinity of the ganglioside GM1 and the anti-CT- B antibody binding to V.
cholerae serotypes O1 and O139 and to CT- B (Figure 17). Two sets of ten-fold serial
dilutions were made for both V. cholerae O1 and V. cholerae O139. One set of dilutions
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was boiled for 10 minutes, whereas the other set was composed of viable cells. Ten-fold
serial dilutions were also made of CT-B (initial concentration at 1 mg/ml).
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FIGURE 17. Sandwich ELISA with GM1 as capture molecule and anti-CT-B antibody as
detection molecule for detection of CT- B and V. cholerae serotypes. Tenfold dilutions
of V. cholerae serotype O1 (▪; 1.62 x 109 cfu/ml), V. cholerae serotype O1 boiled
(▲;1.62 x 109 cfu/ml), V. cholerae serotype O139 (■; 7.3 x 108 cfu/ml), V. cholerae
serotype O139 boiled (x; 7.3 x 108 cfu/ml) and CT- β (♦; 1mg/ml) were done in duplicate.
Error bars (⊥) indicate the standard deviation of the means.

When the GM1 was used for capture and the anti-CT- B antibody was used for
detection, there is no cross-reactivity to cells. The sandwich ELISA was capable of
detecting CT-B at a dilution of 10-5 which corresponds to concentration of 10 ng/ml. The
sandwich ELISA shows no reactivity to V. cholerae cells. The cells themselves will not
be a source of false positives, they must produce CT- B for positive detection.
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CT Standard Curve
A standard curve was generated using the sandwich ELISA as previously
described (Figure 18). Assays using the Analyte 2000 (Figure 19) are also shown. GM1coated wells or waveguides were prepared at a concentration of 1.5 µg/ml. Serial
dilutions of CT- β were added to the wells or waveguides and incubated for 10 minutes.
After washing, anti-CT- B antibody was added to wells or waveguides. Antibody was
detected using secondary antibody for ELISA or by a direct Cy5 label for the Analyte
2000. Sample values for the Analyte 2000 were normalized (as previously described)
using 100 ng/ml as the standard. For all ELISA assays, a signal to noise value greater
than 2 was treated as a positive signal. The sensitivity of the ELISA was approximately
0.625 ng/ml CT-B.

10.0

Signal to noise ratio

8.0
6.0
4.0
2.0
0.0
0.313

0.625

1.25

2.5

5

10

CT-B concentration in ng/ml

FIGURE 18. Mean value for ELISA CT-B standard curve. Sandwich ELISA with GM1
as capture molecule and anti-CT-B antibody as detection molecule. Mean value for three
separate assays.
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FIGURE 19. Analyte 2000 normalized standard curve of CT-B. Mean normalized
values for 21 waveguides.

The average normalized values and standard deviations for the three serial
dilutions of 1 mg/ml CT-B are listed in Table 7. The limit of detection for the Analyte
2000 assay was 1 ng/ml. The Analyte 2000 assay has a greater dynamic range of
detection. It detects 1 ng/ml to 100 ng/ml of CT-B while the ELISA becomes saturated at
CT-B of 2.5 ng/ml.

TABLE 7. Average normalized ∆pA values and standard deviations for CT-B standard
curve using the Analyte 2000.
CT-B concentration

Average normalized value

Standard deviation

0.1 ng/ml
1 ng/ml
10 ng/ml

1.6
4.2
24.8

1.53
0.95
3.83
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Sensitivity of Antibody Versus Ganglioside as Capture Molecule
An Analyte 2000 assay comparison was done using ant-CT-B antibody as the
capture molecule versus the ganglioside, GM1, as the capture molecule. The assay was
performed in order to determine if one of the biomolecules was more effective at
capturing CT- B. Two waveguides were incubated with GM1 for 18 hours at 1.5 µg/ml
in a 37°C incubator. Two waveguides were incubated with 100 µl of 100 µg/ml
streptavidin for 18 hours at 4°C. The following day the waveguides were rinsed with 5
ml PBST and 100 µl of 50 µg/ml of biotin-labeled anti-CT- β antibody was incubated
with the two waveguides containing streptavidin at 24° C for one hour. The standard
biosensor assay protocol using Cy5-anti-CT- B antibody for detection was followed.
Figure 20 illustrates that the ganglioside GM1 as a capture molecule produced the same
levels of detection sensitivity as the anti-CT- B antibody: 1 ng/ml.
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FIGURE 20. Comparison of anti-CT- B antibody (♦) versus GM1 ganglioside-based (▪)
capture assay using the Analyte 2000. Cy5-anti-CT- B antibody was used for detection
in both assays. Error bars are present, but not visible with some data points because they
are so small.
Signal Amplification
A secondary antibody that would bind the Fc portion of the anti-CT-β antibody
was used to amplify the pA signal of the Analyte assay (Figure 21). Amplification of the
signal may allow detection of lower concentrations of CT- B. The secondary antibody,
Cy5-labeled anti-rabbit-IgG, was preincubated with the primary antibody (anti-CT- B) at
a ratio of 1:2 prior to incubation on each waveguide. The same biosensor assay protocol
was followed, but the antibody mixture was used as the detection antibody.
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FIGURE 21. Comparison of biosensor assay using Cy5-anti-CT- B antibody (▪) or a
mixture of anti-CT- B antibody and Cy5-anti-rabbit IgG (♦) as the detection reagent.

The average normalized ∆pA values and standard deviations for the three serial
dilutions of 1 mg/ml CT- B are listed Table 8. The trends in variability in normalized
values for signal amplification were the same as those seen in the CT standard curve.
Adding a secondary antibody did not increase the sensitivity of the assay. The limit of
detection for the assay was determined to be the same as the assay with no signal
amplification: 1 ng/ml CT-B.
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TABLE 8. Average normalized ∆pA values and standard deviations for signal
amplification using the Analyte 2000.
CT-B concentration

Average normalized value

Standard deviation

0.1 ng/ml
1 ng/ml
10 ng/ml

0.3
2.3
20.0

0.3
0.8
5.1

The signal amplification did not cause an increase in sensitivity of the assay. The
average normalized values were lower for signal amplification than with a primary
antibody only (Table 7 and 8). Figure 21 demonstrates that there is no advantage to using
a secondary antibody.
Toxin Induction
ELISA and Analyte 2000 utilizing CT. Vibrio cholerae cells produce the
holotoxin CT, not just CT-B. In previous ELISA and Analyte 2000 assays, a
commercially modified CT-B was used to generate data. There was a concern that
ELISA and biosensor results would change when testing the holotoxin, CT. With the
ELISA, it became necessary to lower the anti-CT- B antibody concentration to 310
ng/ml. The concentration used in previously reported assays was 10 µg/ml, but the range
of detection was low (0.1-5 ng/ml) because the antibody saturated the signal. The
detection antibody concentration remained 10 µg/ml for the Analyte 2000 assays.
Detection of CT instead of CT- B produced results with a sensitivity similar to the one
obtained with the ELISA (Figure 22) and the Analyte 2000 (Figure 23): 1 ng/ml.
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FIGURE 22. ELISA values for CT standard curve assay. Standard curve values are the
mean of four assays.
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FIGURE 23. Standard curve for CT using Analyte 2000. The ∆pA values are the mean
from eight waveguides.
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The average normalized ∆pA values were higher and the standard deviations were
lower when CT was utilized in the assay instead of CT-B (Table 9). However, the limit
of detection when using CT was the same as when testing CT- B: 1 ng/ml.

TABLE 9. Average normalized ∆pA values and standard deviations for CT standard
curve using the Analyte 2000.
CT concentration

Average normalized value

Standard deviation

0.1 ng/ml
1 ng/ml
10 ng/ml

2.5
5.9
28.2

1.2
1.4
3.9

CAYE as induction medium. Using the Miniami et al. protocol, three strains of V.
cholerae were induced in vitro to produce cholera toxin: Vibrio cholerae Pacini 569B
ATCC 25870, Vibrio cholerae Pacini El Tor ATCC 39050 and Vibrio cholerae O1 El
Tor Inaba CDC (108). Cholera toxin was detected by ELISA and Analyte 2000 without
signal amplification (Table 10).
Cell counts of 108 cfu/ml or higher were needed to induce CT production. Vibrio
cholerae O1 Classical 569B ATCC 25870 is considered to be the ideal CT producing
strain (44). Based on the values in Table 10, this organism produced the greatest amount
of CT. Both V. cholerae El Tor strains produced lower levels of CT and were not ideal
toxin producers. Signal saturation occurred at approximate CT concentrations of 5 ng/ml
in ELISAs for CT. Analyte 2000 normalized values greater than 5.9 (Table 9), the limit
of detection for 1 ng/ml from the CT standard curve assay, were treated as positives.
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V. cholerae O1 Classical 569B ATCC 25870 was the only strain that had positive values
for all of the assays utilizing both methods of detection. High concentrations (>108
cfu/ml) of V. cholerae O1 El Tor ATCC 39050 never produced positive signals with the
Analyte 2000 and had 60% (3/5) positive ELISA tests. The V. cholerae O1 El Tor
(received from the CDC) was not any more efficient at CT production than the ATCC El
Tor strain. The CDC El Tor strain never generated positive signals with the Analyte
2000 and had 80% (4/5) positive ELISA tests for CT production. The concentration of
primary antibody used for an ELISA was 310 ng/ml, while 10 µg/ml of detection
antibody was used with the Analyte 2000. The difference in antibody concentration
could account for positive signals generated with the ELISA and not the Analyte 2000.
Based on the higher values shown for CT production in Table 10, V. cholerae O1
Classical 569B ATCC 25870 was selected as the strain to use in future induction assays.
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TABLE 10. Cholera toxin induction values utilizing an ELISA and the Analyte 2000.
Viable count

Analyte 2000
normalized value

5.9 x 108 cfu/ml
3.0 x 109 cfu/ml
4.2 x 109 cfu/ml

1.6
3.4
53.5

3.7
3.9
4

1.85 x 109 cfu/ml
1.36 x 109 cfu/ml
3.9 x 109 cfu/ml

0.4
1.6
51.3

3.4
4.4
4.4

Assay 3
V. cholerae O1 El Tor (ATCC 39050) 2.89 x 109 cfu/ml
V. cholerae O1 El Tor (CDC)
2.95 x 109 cfu/ml
V. cholerae O1 Classical 569B
1.07 x 1010 cfu/ml
(ATCC 25870)

0.7
2.7
65.4

2.6
3.8
5.4

Assay 4
V. cholerae O1 El Tor (ATCC 39050)
V. cholerae O1 El Tor (CDC)
V. cholerae O1 Classical 569B
(ATCC 25870)

2.02 x 109 cfu/ml
8.9 x 108 cfu/ml
TNTCa

0.8
2.2
44.8

1.0
1.5
3.4

Assay 5
V. cholerae O1 El Tor (ATCC 39050)
V. cholerae O1 El Tor (CDC)
V. cholerae O1 Classical 569B
(ATCC 25870)

3.7 x 109 cfu/ml
7.4 x 108 cfu/ml
4.7 x 109 cfu/ml

0.7
1.7
55.3

1.0
2.0
3.0

Assay 1
V. cholerae O1 El Tor (ATCC 39050)
V. cholerae O1 El Tor (CDC)
V. cholerae O1 Classical 569B
(ATCC 25870)
Assay 2
V. cholerae O1 El Tor (ATCC 39050)
V. cholerae O1 El Tor (CDC)
V. cholerae O1 Classical 569B
(ATCC 25870)

a

ELISA
signal to noise ratio

Too numerous too count.

Alternate induction media. Vibrio cholerae O1 classical 569B was induced for
CT production using a petri dish and a beaker with a similar surface area to volume ratio
of a 10 gallon tank. For subsequent assays, oysters were harvested from Tampa Bay and
placed in a 10 gallon tank. The medium in the tank needed to serve three essential
functions: 1) maintain the oysters viability 2) allow V. cholerae growth and 3) stimulate
CT production. Four types of media were tested in petri dish and beaker trials: salt water
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culture medium made in DI water (SWC-DI), salt water culture medium made in Instant
Ocean (SWC-IO), CAYE made in Instant Ocean (CAYE-IO) and CAYE in DI water
(CAYE-DI) as the control (Figure 24). The induction protocol previously described was
used to induce CT production.

14

Signal to noise ratio

12
10
8
6
4
2
0
SWC in D I

SWC in IO

CAYE in D I

CAYE in IO

Medium

FIGURE 24. Toxin induction during V. cholerae growth in four types of media. A petri
dish (■) and a beaker (∴) with the same surface to volume ratio of a 10 gallon tank were
used for these assays. SWC in DI, salt water culture medium in deionized water; SWC in
IO, salt water culture medium in instant ocean; CAYE in DI, casamino acids yeast extract
in deionized water; CAYE in IO, casamino acids yeast extract in instant ocean.

All four types of media supported CT production in a petri dish. As seen in Table
11, three of the four petri dish assays produced cell counts that correlated with those in
Table 10. The petri dish culture with the highest cfu/ml (SWC-DI) generated the highest
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signal to noise ratio while the culture that had the lowest cfu/ml (SWC-IO) generated the
lowest signal to noise ratio.
When running the beaker assays, two types of media allowed for toxin
production: SWC-DI and CAYE-IO. The SWC-IO tank simulation failed to support the
growth of any V. cholerae (Table 11). Cell counts for the beaker assays (tank simulation)
never reached those of the petri dishes.

TABLE 11. Viable cell counts for CT induction utilizing alternative media.
Culture conditions

Cell count
4.0 × 109 cfu/ml
1.1 × 107 cfu/ml
3.6 × 109 cfu/ml
3.1 × 109 cfu/ml
9.0 × 107 cfu/ml
0 cfu/ml
3.8 × 107 cfu/ml
3.5 × 108 cfu/ml

Petri dish – SWC-DI
Petri dish – SWC-IO
Petri dish – CAYE-DI (control)
Petri dish – CAYE-IO
Beaker assays – SWC-DI
Beaker assays– SWC-IO
Beaker assays - CAYE-DI (control)
Beaker assays – CAYE-IO

Toxin Spiked Oysters
The detection of CT in an oyster matrix was tested using the Analyte 2000. Store
purchased oysters were processed according to Tamplin and Capers (168). Oysters were
spiked with 10 ng/ml of CT and waveguides were prepared with 1.5 µg/ml of GM1 as
previously described. The assay was done in a progressive manner: buffer was assayed,
followed by assays for an oyster, a spiked oyster and then the CT standard. The limit of
detection was determined for each Analyte 2000 channel. All four of the channels
generated false positives with the unspiked oyster matrix (Table 12). All of the channels
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were positive for the spiked oyster matrix and the standard. Based on the false positives
obtained for the unspiked oyster matrix, it was hypothesized that there were proteins
present that were cross reacting with the detection antibody.
TABLE 12. Toxin spiked oyster homogenate samples analyzed with the Analyte 2000.
This is a representative sample of waveguides tested.
Channel a
1

2

3

4

LOD

13

12

23

38

Change in signal (pA) for
Buffer
Oyster
Spiked oyster
100 ng/ml CT

-3
40.0
383
1781

-4
87
386
1306

-6
111
625
2260

-10
153
375
1377

a

numbers in bold are positive signals.

Cross-Reactive Proteins
Affinity for polyclonal anti-CT-B rabbit antibody. A Western blot was performed
to determine if the Analyte 2000 values shown in Table 12 for the unspiked oyster
homogenate were false positives. Four different oysters were processed and analyzed for
cross-reactive proteins. Electrophoresed proteins transferred onto nitrocellulose filter
were probed with polyclonal anti-CT-B antibody (Figure 25). Two protein bands reacted
with the anti-CT-B (Figure 25). One band had a molecular weight of approximately 100
kD and one had a molecular weight of approximately 60 kD. The CT holotoxin has a
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molecular weight of 85 kD, the A subunit has a molecular weight of 27.2 kD and the B
subunit has a molecular weight of 11.6 kD. CT and CT-B molecular weights do not
correspond with 100 and 60 kD; therefore, the presence of these proteins suggests that the
false positives may be due to cross-reactive proteins
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98

60 kD

47
33
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15
7

FIGURE 25. Western blot of four unspiked oyster samples. Lane 1, marker; Lane 2,
buffer; Lane 3, 75 ng CT- β; Lane 4, unspiked oyster A; Lane 5, unspiked oyster B; Lane
6, unspiked oyster C; Lane 7, unspiked oyster D; Lane 8, 75 ng CT- β.

Affinity for IgG antibody. The Western Blot was repeated in order to determine if
the two cross reactive proteins (100 kD and 60 kD) seen in Figure 25 were binding
specifically to the polyclonal anti-CT-B rabbit antibody (Biogenesis) or just binding
nonspecifically to IgG antibody (Figure 26). Incubation with a primary antibody was
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eliminated and the membrane was incubated directly with anti-rabbit IgG conjugated to
alkaline phosphatase. The only visible bands were those of the molecular weight marker,
indicating the 100 kD and 60 kD cross-reactive proteins were binding specifically to the
anti-CT-B antibody.
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FIGURE 26. Western blot of oyster homogenate utilizing goat anti-rabbit IgG conjugated
to alkaline phosphatase only. Lane 1, marker; Lane 2, 75 ng CT; Lane 3, buffer; Lane 4,
oyster homogenate spiked with 10 ng/ml CT; Lane 5, buffer; Lane 6, oyster homogenate;
Lane 7, buffer; Lane 8, buffer; Lane 9, 75 ng CT; Lane 10, buffer.

Specificity for GM1. ELISAs were performed to determine if the oyster matrix
was binding to GM1. Two types of samples were tested: (1) APW spiked with 100 ng/ml
of CT and (2) unspiked oyster homogenate. Samples were fractionated by size using a
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P10 column and fractions were collected in 500 µl volumes. Samples were directly
adsorbed to wells (Figure 27) or captured using 1.5 µg/ml of GM1 per well (Figure 28).
All of the fractions from both samples were tested.
Figures 27 and 28 illustrate that the oyster homogenate did not exhibit nonspecific
binding to the wells of the 96-well microtitre plate. The fractionated oyster homogenate
displayed no specificity or binding activity with the ganglioside GM1. All 10 fractions
had a signal to noise ratio of less than 2 and, therefore, were considered negative. ELISA
results would also indicate the level of nonspecific binding of the oyster matrix to the
plate and to GM1. It was concluded based on Figures 27 and 28 that the cross-reactive
proteins bind to anti-CT-B antibody and do not bind to GM1.
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FIGURE 27. ELISA values for fractions of oyster sample adsorbed directly to ELISA
wells. Ten fractions from oyster homogenate (♦) and APW spiked with 100 ng/ml CT (▪)
were tested for binding to GM1.
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FIGURE 28. ELISA values for GM1 based assay. Ten fractions from oyster homogenate
(♦) and APW spiked with 100 ng/ml CT (▪) were tested for binding to GM1.

Removal of cross-reactive proteins from oyster matrix. The cross-reactive
proteins in the oyster were removed by passage through a P10 gel bed. Five hundred
microliters of oyster homogenate spiked with 5 µg/ml of CT and unspiked oyster
homogenate were passed through two separate P10 columns with a 10 ml bed volume.
The columns were equilibrated with PBS with 0.1% sodium azide. Ten 500 µl fractions
were collected and analyzed using an ELISA (Figure 29) and the Analyte 2000 (Table
13). Fractions 6 through 10 contained the cholera toxin from the spiked sample. None of
the fractions from the unspiked sample contained cholera toxin or other proteins that
would generate a positive ELISA signal. According to ELISA results, fractions 7 and 8
should have high concentrations of CT. Fractions 7 and 8, were analyzed using the
Analyte 2000 (Table 13). Positive signals were generated when fractions 7 and 8 of the
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spiked sample were assayed. Negative signals were obtained for the nonspiked fractions
7 and 8. Fractionating the oyster matrix through the gel column may have removed the
cross-reactive proteins or diluted them to undetectable concentrations.
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FIGURE 29. ELISA values for oyster homogenate fractions. Oyster homogenate spiked
with 5 µg/ml of CT (♦) and unspiked oyster homogenate (▪) were fractionated. All ten
fractions from each sample were tested.
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TABLE 13. Analyte 2000 values for oyster homogenate fractions.
Channela
1

2

Fraction 7
spiked

Fraction 8
spiked

3

4

Fraction 7
unspiked

Fraction 8
unspiked

LOD

0

4

7

36

Change in signal for
APW
Sample

-1
899

0
645

-2
0

-1
-1

a

numbers in bold are positive signals.

Tank Inoculation
Instant Ocean as induction medium. A 10 gallon aquarium was filled with 10 L of
Instant Ocean. The temperature of the tank was maintained at 30 °C. This is the
optimum temperature to induce CT production. Oysters were harvested from Tampa Bay
during low tide. The oysters were scrubbed to remove loose particles and placed in the
aquarium. Oyster shells remained closed confirming viability. After 24 hours,
V. cholerae O1 569B ATCC 25870, was inoculated into the tank at a final concentration
of 7.27 × 104 cfu/ml. Organisms were enumerated with alkaline peptone broth by the
five tube MPN enrichment method. After 6 hours of incubation in a 42°C waterbath, all
turbid tubes were streaked on TCBS agar for the isolation of V. cholerae (41, 111).
V. cholerae was identified using PCR and API 20E. V. cholerae and other bacteria were
recovered from the oyster and Instant Ocean at 6 and 12 hours and presumptively
identified by API 20E (Table 14). Table 15 lists the cfu/g (oyster matrix) or cfu/ml (tank
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medium) determined by a 5 tube MPN. V. cholerae was no longer recovered from the
oyster or Instant Ocean after 12 hours of incubation. Cell counts listed in Table 15 were
at least 1000-times lower than those observed using the petri plate toxin induction
method. The lower cell counts suggested that V. cholerae cells would not produce toxin.
The ELISA values (Figure 30) confirmed the lack of CT production.

TABLE 14. Isolates presumptively identified by API 20E for Instant Ocean tank. tc,
control oysters processed at time of harvest; t0, samples placed in tank, processed 24
hours after harvest and immediately prior to tank inoculation; t6, t12, t24, t48, and t72,
samples processed 6, 12, 24, 48, and 72 hours after tank inoculation respectively; oyster
or Instant Ocean, type of sample.
Time point and sample at collection
Control oyster - tc
Oyster – t0
Instant Ocean – t0
Oyster – t6
Instant Ocean – t6
Oyster – t12
Instant Ocean – t12
Oyster – t24
Instant Ocean – t24
Oyster – t48
Instant Ocean – t48
Oyster – t72
Instant Ocean – t72

Isolate identification
Aeromonas hydrophila, Klebsiella ozaenae,
Vibrio parahaemolyticus
Klebsiella ozaenae
Vibrio parahaemolyticus
Escherichia coli, Vibrio cholerae
Vibrio parahaemolyticus, Vibrio fluvialis,
Vibrio cholerae
Vibrio parahaemolyticus, Vibrio cholerae
Vibrio fluvialis, Vibrio cholerae
Vibrio fluvialis
Vibrio fluvialis
Aeromonas hydrophila
Vibrio fluvialis
unidentifiable
Escherichia coli
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TABLE 15. Cell counts for Vibrio cholerae recovered from oyster and Instant Ocean. t6,
and t12, samples processed 6 and 12 hours after tank inoculation; oyster or Instant Ocean,
type of sample.
Time point and sample at collection

Cell count
4.0 × 104 cfu/g
2.5 × 104 cfu/ml
6.5 × 103 cfu/g
6.5 × 104 cfu/ml

Oyster – t6
Instant Ocean – t6
Oyster – t12
Instant Ocean – t12
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FIGURE 30. ELISA values for samples from tank inoculation with Instant Ocean.
Oyster homogenate was fractionated as described previously and assayed for the presence
of CT. Control oysters (♦), oysters at t0 (▪), oysters at t6 (▲) and oysters at t12 (■) were
all negative for CT.
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Isolates presumptively identified by API 20E as V. cholerae were confirmed by
PCR using two sets of primers and predicted lengths: its (Figure 31) and ctxA (Figure
32). The its primers were designed to amplify the 16S-23S rRNA intergeneic spacer
region of V. cholerae (21). The ctxA primers were designed to amplify the genes
encoding the A subunit of CT (48). Figure 31 shows positive amplification of its gene
from V. cholerae isolates at 6 and 12 hour time points. Figure 32 shows positive
amplification of ctxA gene from V. cholerae isolates at both time points.
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FIGURE 31. PCR of isolates using its primers. Lane1, ladder; Lane 2, positive control
V. cholerae; Lane 3, negative control E. coli; Lane 4, presumptive V. cholerae from
oyster at t6; Lane 5, presumptive V. cholerae from Instant Ocean at t6; Lane 6,
presumptive V. cholerae from oyster at t12; Lane 7, Presumptive Vibrio cholerae from
Instant Ocean at t12.
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FIGURE 32. PCR of isolates using ctxA primers. Lane 1, ladder; Lane 2, positive control
V. cholerae; Lane 3, negative control E. coli; lane 4, presumptive V. cholerae from oyster
at t6; Lane 5, presumptive V. cholerae from Instant Ocean at t6; Lane 6, presumptive V.
cholerae from oyster at t12; Lane 7, presumptive V. cholerae from Instant Ocean at t12;
.
SWC-DI as induction medium. SWC-DI simulates the previously described petri
dish protocol. A 10 gallon aquarium was filled with 10 L of SWC-DI. The temperature
of the tank was maintained at 30°C. Oysters harvested from Tampa Bay were placed in
the aquarium for 24 hours. Vibrio cholerae O1 569B ATCC 25870 was then inoculated
into the tank at a final concentration of 4.56 × 104 cfu/ml. After 0, 6, 12, 24, and 48 hour
time points organisms were recovered from the oyster matrix and the tank medium.
Table 16 lists those isolates presumptively identified by API 20E. Vibrio cholerae was
not recovered from the oyster matrix or the SWC medium at any time interval. The
inability to recover any V. cholerae leads to the conclusion that it would be highly
unlikely that CT production would have occurred. The ELISA testing for the presence of
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CT (Figure 33) confirmed the lack of CT production within the oyster matrix or tank
medium.

TABLE 16. Isolates presumptively identified by API 20E for SWC-DI tank. Oyster and
tank medium samples were collected at varying time intervals. Ten oysters from each
tank were scrubbed, their meat pooled and homogenized 1:1 in PBS followed by serial
dilution in PBS (111). A five tube MPN was prepared by enriching dilutions of oyster
homogenate or tank medium in APW (pH 8.5) at 42°C for 6 hours in a water bath. Each
tube in the MPN series was then streaked onto TCBS (41). Plates were incubated at 37°
C for 18 hours. Individual colonies were resuspended in PBS for presumptive
identification by API 20E. tc, control oysters processed at time of harvest; t0, samples
placed in tank, processed 24 hours after harvest and immediately prior to tank
inoculation; t6, t12, t24, and t48, samples processed 6, 12, 24, and 48 hours after tank
inoculation, respectively; oyster or Instant Ocean, type of sample.
Time point and sample at collection

Isolate identification

Control oyster - tc
Oyster – t0
SWC-DI – t0
Oyster – t6
SWC-DI – t6
Oyster – t12
SWC-DI – t12
Oyster – t24
SWC-DI – t24
Oyster – t48
SWC-DI – t48

Vibrio parahaemolyticus
Vibrio parahaemolyticus
Vibrio parahaemolyticus
Vibrio alginolyticus
unidentifiable
Vibrio parahaemolyticus
Escherichia coli
Vibrio alginolyticus
Vibrio alginolyticus
No growth
Vibrio alginolyticus
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FIGURE 33. ELISA for the detection of CT after V. cholerae inoculation of tank
containing SWC-DI. Oyster samples (■) and SWC-DI (∴) were assayed at different time
intervals for the presence of CT. The ganglioside GM1 was used as the capture molecule
and the primary antibody was the anti-CT antibody. A signal to noise ratio greater than 2
was a positive value.

CAYE-IO as induction medium. CAYE-IO simulates the previously described
petri dish protocol. A 10 gallon aquarium was filled with 10 L of CAYE-IO and was
inoculated with V. cholerae. The temperature of the tank was maintained at 30°C. At 24
hours post inoculation, ten mls of the liquid was transferred to a new tank containing
CAYE-IO with 0.2% glucose. The in vitro induction assays described previously utilized
fresh CAYE medium with 0.2% glucose for CT induction at 24 hours post inoculation.
Oysters were harvested from Tampa Bay and then added to the aquarium. After 24
hours, V. cholerae O1 569B ATCC 25870, was inoculated into the tank at a final
concentration of 4.56 × 104 cfu/ml. At 0, 6, 12, 24, and 48 hour time points organisms
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were recovered from the oyster matrix and the tank medium. Table 17 lists those isolates
presumptively identified by API 20E. Vibrio cholerae was not recovered from the oyster
or SWC at any time interval. It was unlikely that CT was produced without the growth of
any viable V. cholerae. ELISA detecting the presence of CT (Figure 34) confirmed the
absence of CT production.

TABLE 17. Isolates presumptively identified by API 20E recovered from CAYE-IO with
0.2% glucose tank. tc, control oysters processed at time of harvest; t0, samples placed in
tank, processed 24 hours after harvest and immediately prior to tank inoculation; t6, t12,
t24, and t48, samples processed 6, 12, 24, and 48 hours after tank inoculation, respectively;
oyster or Instant Ocean, type of sample.

Time point and sample at collection

Isolate identification

Control oyster - tc
Oyster – t0
CAYE – t0
Oyster – t6

Vibrio parahaemolyticus
Vibrio parahaemolyticus
Vibrio parahaemolyticus
Vibrio alginolyticus, Vibrio
parahaemolyticus
Vibrio alginolyticus, Vibrio
parahaemolyticus
Vibrio alginolyticus
Vibrio alginolyticus
Vibrio alginolyticus
Vibrio alginolyticus
No growth
Vibrio alginolyticus

CAYE – t6
Oyster – t12
CAYE – t12
Oyster – t24
CAYE – t24
Oyster – t48
CAYE with 0.2% glucose – t48
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FIGURE 34. ELISA detecting presence of CT from tank containing CAYE-IO with
0.2% glucose, inoculated with V. cholerae. Oyster samples (■) and CAYE-IO with 0.2%
glucose (∴) were assayed at different time intervals for the presence of CT. All samples
assayed were negative for CT.

Biosensor Immunoassay Development for the Detection of Botulinum Toxin
BCA Protein Assay
No concentrations were provided with the botulinum toxoids received from the
CDC. Only dilution factors were given: type A @ 1:10,000 and type B @ 1:1,000. A
BCA protein assay was performed to determine the actual protein concentration of each
toxoid. The correlation coefficient (r) of the line was 0.997. The extrapolated values are
listed in Table 18 but their validity is questionable. The absorbance readings for each of
the toxoids were below the reading of the lowest known BCA concentration and,
therefore, determined to be invalid. Thus, it was determined that the dilutions to be tested
would be based on the CDC stock suspension.
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TABLE 18. Extrapolated botulinum toxoid protein concentrations.
Protein concentration
0 mg/ml BSA
0.1 mg/ml BSA
0.2 mg/ml BSA
0.4 mg/ml BSA
0.6 mg/ml BSA
0.8 mg/ml BSA
1 mg/ml BSA
Toxoid A
Toxoid B

Absorbance @ 562 nm

Extrapolated concentration

0
0.039
0.079
0.137
0.181
0.240
0.296
0.019
0.016

0.018 mg/ml
0.028 mg/ml

ELISA for Detection of Botulinum Toxoids Using Anti-Botulinum Antibody
Anti-botulinum toxoid antibodies obtained commercially and from the CDC
(Figure 35) were tested for their ability to bind to botulinum toxoids A and B using an
ELISA. Serial dilutions of botulinum toxoids A and B were directly adsorbed to the
wells of a 96-well microtitre plate. Antibodies to toxoid type A and type B were used as
primary antibodies at a concentration of 10 µg/ml. Secondary antibody, anti-rabbit IgG
conjugated to HRP or anti-goat IgG conjugated to HRP was used at a dilution of 1:500.
The polyclonal anti-A botulinum toxin antibody produced in goat and the polyclonal antiB antibody produced in rabbit, both received from the CDC, bound to their respective
toxoids (Figure 35). The CDC anti-toxin A antibody bound toxoid A and could be
detected at dilutions of 1:100,000 and 1:1,000,000, whereas the CDC ant-toxin B
antibody bound to toxoid B and could be detected when the toxoid was diluted 1:10,000.
The Accurate Chemical and Scientific Corporation antibody binding to toxoids A and B
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could not be detected. The CDC polyclonal anti-B goat antibody binding to toxoid B
could not be detected.
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FIGURE 35. Detection of botulinum toxoids adsorbed to plate using anti-botulinum
toxin antibodies. Antibody affinity for toxoid A and B was tested using an ELISA.
Botulinum toxoid A and B were detected using antibodies provided by the CDC or
purchased from Accurate Chemical and Scientific Corporation. Initial concentration of
toxoid A was 1:10,000 and type B was 1:1,000. Combinations of Toxoid A with the
CDC goat anti-A antibody (♦), Toxoid A with the Accurate antibody (▪), Toxoid B with
the CDC goat anti-B antibody (▲), Toxoid B with the CDC rabbit anti-B antibody (■)
and Toxoid B with the Accurate antibody (▬) were all assayed using an ELISA.

Detection of Botulinum Toxoids Using Sandwich ELISA with GT1b Capture
A sandwich ELISA was performed with the ganglioside, GT1b in PBS (1.5
µg/ml) (Figure 36), as a capture molecule. GT1b was directly adsorbed to the wells of a
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mirotitre plate. Serial dilutions of toxoid A and B were captured by the GT1b.
Commercial or CDC antibodies to toxoid type A and type B were used as primary
antibodies to detect either toxoids. Secondary antibody diluted 1:500 was either antirabbit IgG or anti-goat IgG–HRP conjugated. The signal to noise ratio never reached a
value of 2. The ganglioside GT1b showed no specificity for either botulinum toxoids.
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FIGURE 36. Detection of toxoids A and B using sandwich ELISA with GT1b capture.
GT1b (1.5 µg/ml) affinity for toxoid A and B was tested using an ELISA. Botulinum
toxoid A and B were detected using antibodies provided by the CDC or purchased from
Accurate Chemical and Scientific Corporation. Initial concentration of toxoid A was
1:10,000 and type B was 1:1,000. Combinations of Toxoid A with the CDC goat anti-A
antibody (■), Toxoid A with the Accurate antibody (∗), Toxoid B with the CDC goat
anti-B antibody (▪), Toxoid B with the CDC rabbit anti-B antibody (▲) and Toxoid B
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with the Accurate antibody (♦) were all assayed using an ELISA. All five combinations
produced results that overlapped when graphed.

GT1b-and GD1b-Based ELISA
Two of the natural cellular receptors for botulinum toxins are the gangliosides
GT1b and GD1b. These receptors were used as capture molecules in the development of
an ELISA. Since no positive signal was obtained when the GT1b was used as a capture
molecule, another ganglioside, GD1b was tested as a capture molecule. An ELISA was
performed to determine if there was any specificity between the ganglioside GD1b for
botulinum toxoid A and/or B (Figure 37). GD1b was dissolved in PBS at a concentration
of 1.5 µg/ml. The primary antibodies used were the CDC goat anti-A and CDC rabbit
anti-B at a concentration of 10 µg/ml. The secondary antibody was diluted 1:500 and
was either anti-rabbit IgG or anti-goat IgG–HRP conjugated. Neither toxoid could be
detected using the GD1b capture/antibody detection ELISA format. Signal to noise ratios
were below 2 for botulinum toxoid A at 1:100,000 dilution and toxoid B at a 1:10,000
dilution. GD1b had no affinity for either botulinal toxoid A or B (Figure 37).
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FIGURE 37. Detection of botulinum toxoids A or B using GD1b capture in ELISA.
GD1b (1.5 µg/ml) affinity for toxoid A and B was tested using an ELISA. Botulinum
toxoid A and B were diluted 1:10 and detected using antibodies provided by the CDC.
Initial concentration of toxoid A was 1:10,000 and type B was 1:1,000.
Biosensor Assay Detecting Toxoid Type A Using Liposomes
Singh et al. (156) demonstrated that the incorporation of the ganglioside into a
liposome may allow successful detection of botulinum toxin (156). Liposomes
containing Alexafluor 647 were synthesized following the specifications of Singh et al.
(156) for use as a detection molecule in conjunction with the Analyte 2000. Due to the
fluorophore that was incorporated into the liposome being out of the spectral range of the
fluorometer, the normal progression in the development of a biosensor assay could not be
followed. The assay development was initiated with the Analyte 2000. Toxoid A (1:10
or 1:100) was adsorbed directly to the waveguide and allowed to incubate for 18 hours at
4°C. The waveguides were rinsed with PBS and then incubated in blocking buffer (PBS,
2 mg/ml casein, 2 mg/ml BSA) and allowed to incubate 18 hours at 4°C. The
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waveguides were then rinsed with PBS and liposomes at a dilution of 1:1,000 were
incubated on the waveguides for 10 minutes. Table 19 shows representative results from
a single waveguide assay. There was a significant increase in pA signal after incubation
with the liposome followed by PBS rinses for all five channels including the negative
control (Table 19),

TABLE 19. Biosensor values for toxoid A adsorbed directly to the waveguide.
Waveguides were incubated with toxoid A for 18 hours, followed by blocking buffer for
18 hours and then incubated with liposome at a 1:1,000 dilution. Fluorescent readings
were recorded for each step of the assay. Numbers in parentheses indicate incubation
times.
Channel
1

2

3

4

Negative
control

Toxoid concentration

1:100

1:100

1:10

1:10

PBS

Initial waveguide
fluorescence

891

1093

1196

1277

670

1393
5271
8440

2930
7563
15395

20431
22578
22577

6945
6522
17349

1168
2981
4254

4975

834

5763

4618

1284

Signal (pA) after assay step

0.2 ml liposome (5 min)
Two × 1 ml PBS wash
0.2 ml PBST (5 min)
Two × 1 ml PBS wash
(final reading)

Singh et al. (156) reported that incubation with a detergent (such as PBST or
Triton X) after addition of liposome disrupts the liposomes and alleviates dequenching of
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the fluorophore, maximizing fluorescent readings. Following incubation with PBST for 5
min, signals increased dramatically with the exception of channel 3, which had reached
the upper limitations of the machine’s pA signal readout capabilities. After incubation
with PBST, two 1 ml rinses with PBS removed any unbound liposomes causing the pA
signal to decrease. However, for channels 1, 3, 4, and 5, the pA signal after the final PBS
rinse was still higher than that prior to liposome incubation. There was a three-to-fivefold increase in the final fluorescence compared with the initial reading. The negative
control illustrates a substantial amount of liposomes non-specifically sticking to the
waveguide. The final reading obtained for the negative control waveguide was double
the initial fluorescence reading. A direct sandwich assay format utilizing antibody for
capture and the liposomes as a detection molecule was attempted.
Biosensor Assay Utilizing Antibody as a Capture Molecule
Varying liposome concentrations as detection molecule for the detection of
botulinal toxoid type A. Multiple sandwich biosensor assays were performed utilizing
different concentrations of liposome as the detection molecule. Following 18 hours
incubation with streptavidin, biotinylated goat anti-A antibody (100 µg/ml) was
incubated for 18 hours at 4°C. On the following day, the waveguides were rinsed with
PBS and then incubated for 18 hours at 4°C in blocking buffer. On the final day, the
waveguides were rinsed with PBS and an assay was completed with the liposome as the
detection molecule. Initially liposomes at 1:1,000 to 1:5,000 dilutions were used as the
detection reagent (Table 20 and 21). Biosensor assays using these dilutions of liposome
produced very high LODs ranging from 117 to 3162. Table 22 shows results from
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biosensor assay for the detection of toxoid A using liposomes diluted 1:10,000 and
1:20,000 for the detection reagent.

TABLE 20. Sandwich biosensor assay using anti-toxoid A antibody for capture and
liposomes at 1:1,000 as the detection reagent for the detection of botulinal toxoid type A.
Fluorescent readings were recorded for each step of the assay. Numbers in parentheses
indicate incubation times. The limit of detection remained high and the botulinum toxoid
type A was never utilized in the assay.
Channela
1
1:1000

2
1:1000

3
1:1000

4
1:1000

0.2 ml liposome (5 min)
2 × 1 ml PBS wash
0.2 ml PBST (5 min)
2 × 1 ml PBS wash

5995
7449
6036

2656
7913
4172

6104
11139
2075

3032
3869
2265

0.2 ml liposome (5 min)
2× 1 ml PBS wash
0.2 ml PBST (5 min)
2 × 1 ml PBS wash

6782
6941
5880

3549
4909
2984

5937
10143
3965

3175
3880
2874

0.2 ml liposome (5 min)
2 × 1 ml PBS wash
0.2 ml PBST (5 min)
2 × 1 ml PBS wash

5622
5844
5371

1856
3259
1775

2876
3984
2009

3202
3411
1776

0.2 ml liposome (5 min)
2 × 1 ml PBS wash
0.2 ml PBST (5 min)
2 × 1 ml PBS wash

5870
6130
5465

1519
1871
1224

2098
3021
1462

2142
2580
1582

2958

3162

1502

Liposome concentration
Signal (pA) after assay step

LOD
624
a
numbers in italics are limits of detection.
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TABLE 21. Sandwich biosensor assay using anti-toxoid A antibody for capture and
liposomes at 1:2,500 and 1:5,000 as the detection reagent for the detection of botulinal
toxoid type A. Fluorescent readings were recorded for each step of the assay. Numbers
in parentheses indicate incubation times. The limit of detection remained high and the
botulinum toxoid type A was never utilized in the assay.
Channela
1
1:2500

2
1:2500

3
1:5000

4
1:5000

0.2 ml liposome (5 min)
2 × 1 ml PBS wash
0.2 ml PBST (5 min)
2 × 1 ml PBS wash

1529
2206
953

1976
3102
1485

2013
2650
1790

1356
1715
1426

0.2 ml liposome (5 min)
2 × 1 ml PBS wash
0.2 ml PBST (5 min)
2 × 1 ml PBS wash

881
1359
934

1843
2335
1429

1671
1970
1632

1137
1311
1207

0.2 ml liposome (5 min)
2 × 1 ml PBS wash
0.2 ml PBST (5 min)
2 × 1 ml PBS wash

1008
1197
903

1491
1635
1257

1488
1674
1372

1111
1173
1120

0.2 ml liposome (5 min)
2 × 1 ml PBS wash
0.2 ml PBST (5 min)
2 × 1 ml PBS wash

848
949
832

1106
1236
1037

1254
1344
1196

1015
1071
973

LOD

117

455

596

417

Liposome concentration
Signal (pA) after assay step

a

numbers in italics are limits of detection.
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The LODs (Table 20 and 21) were too high to continue with either assay. Although the
assay for cholera toxin utilized the ganglioside as a capture molecule, the LOD obtained
never exceeded values of 40. When a capture antibody was utilized in the botulinum
assay, a trend in signals across all four channels was observed: the fluorescence
continued to decrease with the addition of liposome followed by subsequent washes. A
great deal of variability remained in the background signals and a low LOD was never
attained.
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TABLE 22. Sandwich biosensor assay using anti-toxoid A antibody for capture and
liposomes at 1:10,000 and 1:20,000 as the detection reagent for the detection of botulinal
toxoid type A. Fluorescent readings were recorded for each step of the assay. Numbers
in parentheses indicate incubation times. The limit of detection remained high and the
botulinum toxoid type A was never utilized in the assay.
Channela
1
1:10000

2
1:10000

3
1:20000

4
1:20000

0.2 ml liposome (5 min)
2 × 1 ml PBS wash
0.2 ml PBST (5 min)
2 × 1 ml PBS wash

828
807
770

858
933
721

933
951
871

964
957
884

0.2 ml liposome (5 min)
2 × 1 ml PBS wash
0.2 ml PBST (5 min)
2 × 1 ml PBS wash

846
885
789

804
844
695

929
949
850

937
937
872

0.2 ml liposome (5 min)
2 × 1 ml PBS wash
0.2 ml PBST (5 min)
2 × 1 ml PBS wash

798
805
750

766
790
691

926
926
852

895
903
863

0.2 ml liposome (5 min)
2 × 1 ml PBS wash
0.2 ml PBST (5 min)
2 × 1 ml PBS wash

815
845
839

693
693
683

864
883
861

890
887
868

LOD

133

150

79

53

Liposome concentration
Signal (pA) after assay step

a

numbers in italics are limits of detection.
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A 1:10,000 or 1:20,000 dilution of liposome may have eliminated the nonspecific
binding or it is possible that a smaller concentration of liposome eliminated the signal
completely.
An assay was performed with toxoid type A diluted 1:10 in PBS-BSA 0.1%
(Table 23). One hundred ug/ml of goat anti-A antibody was used as the capture
molecule. Varying liposome concentrations were utilized for the detection of the protein.

TABLE 23. Sandwich biosensor assay with varying liposome concentrations for the
detection of botulinal toxoid type A. Fluorescent readings were recorded for each step of
the assay. Numbers in parentheses indicate incubation times. Buffer was assayed
followed by botulinum toxoid type A.
Channela
liposome

1
1:1000

2
1:1250

3
1:2500

4
1:5000

LOD

64

196

73

74

PBS-BSA 0.1%

30

46

-77

-50

1:10 Type A Toxoid

33

-110

-11

-18

Signal (pA) after 5 minute
incubation with liposome

a

numbers in italics are limits of detection.

Changes in signal values higher than the calculated LOD were treated as positive
values. All of the buffer samples generated negative signals (Table 23). Unfortunately,
104

subsequent incubation with the toxoid yielded negative signals as well. The assay for
botulinum toxin with the Analyte 2000 produced LODs that were too high for valid
results or negative signals for the protein of interest. The inherent nature of the liposome
to bind nonspecifically to the surface of the polystyrene waveguide made it an
impractical detection molecule for the botulinum A toxin.
Varying liposome concentrations as detection molecule for the detection of
botulinal toxoid type B. Toxoid type A had a higher degree of probability of generating
positive signals compared to type B toxoid in the Analyte 2000 assay. All of the initial
assays were performed using toxoid type A and the CDC goat anti-A antibody. The
results indicate that the utilization of the liposomes as the detection molecule in
conjunction with the Analyte 2000 was not successful (Table 20, 21, and 22). The
synthesized liposomes were developed for the intended detection of toxoid type B and
type A, since both botulinal toxoids utilize the same receptor, GT1b. Considering the
results for toxoid type A, it would be improbable that the detection of toxoid type B
would be successful. Bearing this in mind, biosensor assays for the detection of toxoid
type B (Tables 24 and 25) were attempted utilizing concentrations of liposome at lower
and higher concentrations of liposome dilution. The same procedure was followed as that
used for toxoid type A with a different capture antibody (biotinylated CDC rabbit anti-B
antibody).
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TABLE 24. Biosensor assay with liposome concentration at 1:1,000 for the detection of
botulinal toxoid type B. Fluorescent readings were recorded for each step of the assay.
Numbers in parentheses indicate incubation times. The limit of detection remained high
and the botulinum toxoid type B was never utilized in the assay.
Channela
1
1:1000

2
1:1000

3
1:1000

4
1:1000

0.2 ml liposome (5 min)
2 × 1 ml PBS wash
0.2 ml PBST (5 min)
2 × 1 ml PBS wash

4261
6466
2036

2975
4072
1964

10755
11955
7242

10724
11737
8513

0.2 ml liposome (5 min)
2 × 1 ml PBS wash
0.2 ml PBST (5 min)
2 × 1 ml PBS wash

3875
4747
1505

3364
4256
1976

7915
8258
6806

8768
9073
8208

0.2 ml liposome (5 min)
2 × 1 ml PBS wash
0.2 ml PBST (5 min)
2 × 1 ml PBS wash

2369
3144
998

2355
2068
12466

6988
7179
6027

8331
8396
8248

0.2 ml liposome (5 min)
2 × 1 ml PBS wash
0.2 ml PBST (5 min)
2 × 1 ml PBS wash

1385
1509
1004

1605
1458
1087

6792
6858
6635

8158
8153
8076

LOD

3124

1130

1024

123

Liposome concentration
Signal (pA) after assay step

a

numbers in italics are limits of detection

106

TABLE 25. Biosensor assay with liposome concentrations of 1:10,000 and 1:20,000 for
the detection of botulinal toxoid type B. Fluorescent readings were recorded for each
step of the assay. Numbers in parentheses indicate incubation times. The limit of
detection remained high and the botulinum toxoid type B was never utilized in the assay.

Channela
1
1:10000

2
1:10000

3
1:20000

4
1:20000

0.2 ml liposome (5 min)
2 × 1 ml PBS wash
0.2 ml PBST (5 min)
2 × 1 ml PBS wash

1426
2259
1396

1212
1557
919

3680
4148
2095

1283
1344
946

0.2 ml liposome (5 min)
2 × 1 ml PBS wash
0.2 ml PBST (5 min)
2 × 1 ml PBS wash

2346
2903
1255

1816
2017
1171

1684
1888
1205

1101
1268
995

0.2 ml liposome (5 min)
2 × 1 ml PBS wash
0.2 ml PBST (5 min)
2 × 1 ml PBS wash

1420
1562
937

990
1064
802

1100
1121
964

1043
1084
904

0.2 ml liposome (5 min)
2 × 1 ml PBS wash
0.2 ml PBST (5 min)
2 × 1 ml PBS wash

895
903
665

915
940
707

958
975
896

921
955
887

LOD

741

672

1258

164

Liposome concentration
Signal (pA) after assay step

a

numbers in italics are limits of detection
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Low limits of detection (<40 based on cholera assays) were never achieved (Table 24 and
25). Due to the inability to reduce the background fluorescence when utilizing liposomes
as the detection molecule, this concluded any further attempt to detect botulinal toxoid.
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DISCUSSION
The exotoxins of V. cholerae and C. botulinum have different cell specificities
and modes of action. Yet, both of these biological toxins can cause serious human
disease. V. cholerae has the potential to cause pandemic illness. C. botulinum produces
one of the deadliest biological toxins known and can kill within 24 hours. Botulism, and
cholera, are rarely seen in the United States and the chances of naturally acquiring one of
these illnesses is low; however, both toxins can be purposefully disseminated and cause
mass disease.
In October of 2001, the world witnessed the response of both public and private
sector agencies to the intentional release of Bacillus anthracis spores through the mail
system. Public health agencies learned with the release of the spores, they would need
access to rapid and sensitive detection methods for the protection of the public health.
Conventional laboratory test methods for the identification of potential bioterrorism
agents may not provide public health care officials with the rapid results needed to
prevent the dissemination of the potential agent. Conventional methods typically require
multiple steps: enrichment, isolation and serological and/or biochemical tests. These
methods are time consuming, resulting in delayed detection and, more importantly, are
difficult to apply in the field. The ability to rapidly and accurately detect contaminated
food and water would serve to reduce the spread of disease. The goal of this research
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was development of a rapid and sensitive ganglioside-based assay for the identification of
cholera and/or botulinum toxins utilizing an evanescent wave biosensor.
Conventional serological tests including co-agglutination tests (72, 128), enzymelinked immunosorbent assays (ELISA) (104, 151) membrane-based assays (172) and
PCR (52) may be used for rapid identification of the etiological agent. The need for
special equipment and trained employees are not the only inherent weaknesses associated
with these methods; problems with cross-reactivity can also hinder the assay (104). The
polymerase chain reaction (PCR) may also be used to detect bacterial pathogens (52);
however, special equipment and trained employees are needed as well as clean facilities
(91). Also, PCR lacks the capability of detecting a protein product from the cell.
Therefore, PCR would be inefficient at detecting either protein from V. cholerae or C.
botulinum. Enrichment from a complex matrix can be used to obtain the necessary
number of organisms to perform an ELISA or PCR; however, this may take an additional
one to two days, thereby negating the test as a rapid method of identification (52, 151).
These shortcomings coupled with the realization that positive identification of the
organism when using an ELISA or PCR does not give an indication of the toxicity
associated with the serotype can make these methods less advantageous than the
detection of the toxic protein (64, 91).
Prompt diagnosis of cholera or botulism is essential to the patient and the health
care worker. Botulism is most effectively treated early after the appearance of symptoms
(13, 148). Of the more than 193 recognized Vibrio cholerae serotypes, only the O1 and
O139 serotypes are capable of causing epidemic and pandemic cholera (20). Rapid
diagnosis of the serotype or the virulence factor is important due to the virulence of the
110

O1 and O139 serotypes and their potential to cause disease. Identification of the
characteristic rice-water stool can allow one to make a presumptive diagnosis; however, a
definitive diagnosis relies on the isolation of the organism from either feces or vomit,
followed by serological and/or chemical tests (78, 112).
The Analyte 2000 fiber optic-based biosensor assay provides an innovative
alternative to conventional methods for obtaining near real-time (20-min) results. Fiberoptic biosensors have been utilized in the detection of the fraction 1 antigen of Yersinia
pestis (10), Clostridium botulinum toxin A (118), pseudexin and ricin toxin (71, 119)
trinitrotoluene (TNT) (90), staphylococcal enterotoxin (169) and bacterial pathogens (37,
38, 43, 86, 92). The biosensor can analyze four samples simultaneously and use a variety
of biomolecules for either capture or detection of the Analyte (92). One advantage of the
Analyte 2000 is the ability to produce specific results in a complex matrix (37, 38, 39, 86,
171).
The CDC currently lists Vibrio cholerae as a category B critical agent (142). A
study done by Levine et al. with American volunteers showed that different dosages of
purified oral CT elicited different responses (88). An oral dose of at least 5 µg was
required to initiate diarrheal symptoms. Based on the LD50 in mice, 313 mg of CT/100 lb
of body weight would be required to cause illness (53). Rowe-Taitt et al. utilized
ganglioside-based assays for the detection of cholera toxin in an indirect immunoassay
using an array biosensor and generated limits of detection of 40 ng/ml and 1 µg/ml
depending on the species the detection antibody was directed against (143). The
sensitivity of the ganglioside-based assay developed in this research was 1 ng/ml. The
assay is sensitive and specific but more importantly, repeatable.
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The Analyte 2000 uses a polystyrene waveguide as the sample platform. There
was always variability with the signals between different waveguides. In order to
account for variation among each waveguide due to the manufacturing process, the
signals from different waveguides were normalized. Normalization was performed by
dividing the sample change in signal by the change in signal of the 100 ng/ml CT
standard and multiplying by 100 (85). Normalization allowed for the comparison of
values between individual waveguides throughout the entire study.
The biosensor assay relies on detection of the analyte based on the distance of the
evanescent wave from the surface of the waveguide. Currently, the evanescent wave is
propagated approximately 100-1000 nm from the surface of the polystyrene waveguide.
Typically, the fluorescence of any fluorophore falling within this distance is reverberated
back into the waveguide and the signal is recorded by a computer in picoAmperes (pA).
The CT toxin assay developed within this project was consistent and reproducible based
primarily on the small size of the protein. Bacteria are large (average E. coli is 1 µm
wide by 6 µm long). A typical sandwich immunoassay consists of an antibody bound to
a solid surface, followed by the binding of the analyte and then the attachment of an
antibody conjugated to a fluorophore. When the analyte is a bacterium, it has a higher
potential for the cell to fall outside of the evanescent wave. In contrast, a small protein
like CT typically falls within the evanescent wave, therby produceing repeatable and
accurate results. The CT assay developed was successful whether the source of the toxin
was commercially purchased or produced naturally by the V. cholerae cells. The ELISA
and Analyte 2000 were able to detect both sources of CT.
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Environmental sources of cholera toxin include contaminated food and water.
Identification of the organism V. cholerae from contaminated water followed by assaying
for either cholera toxin or the ctx gene has been reported (96, 108, 175). Most research
has focused on assaying for the presence of cells in contaminated food and not the
cholera toxin (51, 62, 77, 96, 98, 122, 164). The method developed in this project relies
on assaying for CT in a complex matrix, an oyster. Initially, two cross-reactive proteins
(with molecular weights of approximately 60 and 100 kD) presented problems in
accurately detect the presence of CT. However, fractionating the oyster homogenate via
a P10 column eliminated the cross-reactive proteins. The Analyte 2000 was able to
detect the presence of CT at a concentration of 5 µg/ml in artificially-contaminated
oysters. The only information known about the two cross-reactive proteins is their
approximate molecular weight. It was unexpected to find two proteins within the oyster
matrix that had an affinity for the anti-CT antibody. A future research project could
include sequencing these two proteins as an initial step in identifying them.
With the ability to induce toxin production in vitro and detect the protein in the
oyster tissue using the Analyte 2000, a tank with live oysters was inoculated with a toxinproducing strain of V. cholerae. The aim of the assay was to simulate the ocean
environment with live oysters, introduce V. cholerae into the system, allow the oysters to
concentrate the organism via filter feeding and assay for the production of CT within the
oyster. The Analyte 2000 assay would be utilized to detect the toxin. The success of the
assay was dependent on the ability of the V. cholerae to grow and proliferate within the
tank and the oysters to remain viable. Three different types of media were used to
support the growth and viability of the cells and the oysters: Instant Ocean, SWC-DI and
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CAYE-IO. Instant Ocean is used to maintain a saltwater tank, SWC is used for
enrichment of marine microorganisms, and CAYE was used in this research study for in
vitro toxin production.
Previous assays developed as part of this project showed that in order for in vitro
toxin production to occur, V. cholerae required 24 hours for growth and needed to reach a
concentration of approximately 109 cfu/ml. The Instant Ocean tank was able to support
V. cholerae growth for 12 hours and the oysters remained viable for up to 72 hours. The
maximum cell count obtained from either the oysters or the medium was approximately
104 cfu/ml. Cholera toxin was not detectable in either the oyster or the tank medium.
These results were not unexpected in as much as the cell count was five logs lower than
needed and the cells were not detectable past 12 hours of inoculation with V. cholerae.
The tank with the SWC-DI was less capable of supporting V. cholerae growth and CT
production than the tank with the Instant Ocean. Vibrio cholerae was undetectable at any
time in either the oyster or the tank medium. The oysters in this tank only remained
viable for 24 hours while the tank medium itself turned into a viscous form with little to
no resemblance of the original medium. CT was not detected in the oysters or the tank
medium. The tank with the CAYE-IO has results similar to the SWC-DI tank. Vibrio
cholerae and CT were undetectable at any time in either the oyster or the tank medium.
This tank also turned into a viscous medium and the oysters were dead by 24 hours. Like
the SWC-DI tank, CT went undetected as well.
While V. cholerae was not detected by culturing in two of the three tanks, cells
may have been present. Extensive research has demonstrated that these cells enter the
VBNC state under stressful conditions (7, 26, 66, 73, 157, 187). The physical appearance
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of the tank, the death of the oysters and other small crustaceans, as well as the
proliferation of other Vibrio spp. and other nonbacterial microorganisms may have placed
the cells in a stressful environment. It is also important to recognize the impact on an
isolate when removing it from laboratory growth conditions and placing it into an
environmental simulation: specific genes may be turned on, off, rearranged or lost (109).
It is possible to have the same impact on the genetics of the microorganism when going
from environmental conditions to laboratory conditions.
Vibrio parahaemolyticus and Vibrio alginolyticus were recovered from both tanks
in instances where V. cholerae was not recoverable; these other bacteria could have outcompeted V. cholerae for available nutrients. Molecular methods for the ctxAB gene or
fluorescent microscopy could not be used to determine if the V. cholerae cells were
present in the tank but possibly entered into the VBNC state because the cells were
intentionally inoculated into the tank. Molecular or immunological methods would detect
the DNA or antigenic determinants of the cells that were present as a result of deliberate
inoculation.
It is also important to consider the realistic application of assaying for the toxin in
seawater. The dilution factor the ocean would provide must be taken into consideration.
The toxin may be secreted into the ocean by toxigenic cells but it would be
extraordinarily diluted so that it may never be detected by available conventional
methods. Seawater samples could be concentrated to recover CT in low concentrations.
The inability to detect CT was not a function of the Analyte 2000 but a function of the
tank simulation itself. There were unknown variables in the tank system that did not
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allow for the growth of V. cholerae cells. Without the growth of the cells, there is no CT
expression.
There are many complex interactions required for the growth, proliferation,
expression of virulence and transmission of V. cholerae in the ocean environment (95).
Research by Raskin et al. indicated that the in vivo signals that affect the ToxR regulon in
control of virulence factors in Vibrio cholerae were unknown (131). The regulon can be
induced in vitro by different environmental signals such as pH, osmolarity and
temperature (131). Taking into account the complex environmental interactions and the
lack of knowledge of the signals needed to activate the ToxR regulon, the lack of in vivo
toxin induction in the tank simulation was not totally unexpected.
All of the tank simulations were performed without a filtration system. The
oysters were harvested directly from Tampa Bay and were contaminated with other
bacterial and mycotic organisms. The lack of filtration allowed for the accumulation of
these microorganisms and waste products in the tank environment. If a filter had been
used, then the V. cholerae cells would have been removed from the tank. However, other
cells were allowed to grow and proliferate. The proliferation of these organisms may
have out-competed the V. cholerae for nutrients, thereby making CT production difficult,
if not impossible under these conditions.
The initial in vitro induction assays were performed in pure culture. It may be
advantageous to return to the pure culture petri dish assays in order to determine the
limiting factors in the tank simulation. Future assays could test the effect growth of other
organisms found in the tank simulation have on the toxin-producing capabilities of V.
cholerae.
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One of the first assays attempted with the live oysters was to inoculate a single
oyster in a large beaker (data not reported) and then assay for CT. The experiment failed
because the oyster was unable to survive longer than 6 hours. The development of this
assay was dependent on the survival of the oyster and the growth of V. cholerae. In spite
of the fact that toxin production could not be elicited in the tank simulation, it was
induced in vitro in three separate strains of V. cholerae, which provided a natural source
of the toxin.
A VET-RPLA detection kit (Oxoid) exists on the market that requires 24 hours
enrichment of a pure culture of V. cholerae before the agglutination assay can be
performed (146, 177). The limit of detection for the kit is currently 1-2 ng/ml of CT
(177). The assay developed in this research has the ability to detect CT in the presence of
cells without enrichment within a 20 minute time period with a limit of detection of 1
ng/ml. Conventional methods and VET-RPLA require the growth of the organism. Any
assay requiring enrichment would take longer than the 20 minute required for the Analyte
2000. Molecular methods such as PCR can be used to assay for virulent V. cholerae (21,
96, 98, 122). However, the inhibitory substances present in complex matrices such as
food require sample processing before any testing can be performed (39, 96). The assay
developed in this research was not inhibited by any substances which may be found in the
food matrix. The only problem encountered with the oyster was the presence of two
cross reactive proteins, which was overcome with fractionization of the oyster
homogenate.
The ability of the Analyte 2000 assay to detect CT in a complex food matrix
could be applied to other matrices as well. Fecal material and vomit are two other
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complex matrices in which CT may be found. The utilization of the P10 gel column for
sample fractionation could possibly allow for the detection of cholera toxin in these
matrices. The assay developed in this study showed that, if CT is present at 10 ng/ml or
higher in the oyster matrix, the Analyte 2000 has the capability to detect its presence.
The ganglioside-based assay is a comparable alternative to an antibody-based
assay, (sensitivity of 1 ng/ml). Use of the ganglioside as the capture molecule and the
antibody as the detection molecule conferred double specificity to the assay: receptortoxin specificity and toxin-antibody specificity. The causative agent of cholera is
ultimately CT itself. Toxin detection in lieu of detecting the organism is a more direct
measure of pathogenicity. The assays developed within this project successfully detected
the presence of commercial and natural sources of cholera toxin in buffer, in the presence
of cells and within the matrix of an oyster.
The CDC currently lists Clostridium botulinum toxin as a category A critical
agent (142). With an LD50 of 1 ng/kg of body weight in humans (53, 59, 163), a human
oral lethal dose for type A toxin at 1 µg/kg (47, 163), botulinum toxin is one of the most
potent biological toxins available (29, 53, 59, 163). Unlike the cholera toxin assay
developed in this research, the botulinum assay would need to be extremely sensitive.
Research has shown that detection is possible with a colorimetric ELISA at 20 pg/ml for
type A and B toxin (1), with the mouse bioassay at a MLD of 10-30 pg (47, 181) and
with a ganglioside-liposome immunoassay at a toxin concentration of 15 pg/ml (1).
Consequently, the botulinum assay must have a limit of detection on the order of at least
2-3 logs more sensitive than the cholera toxin assay to be competitive with other assays
available.
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Both the antibodies and type A and B botulinum toxins used for the development
of this assay were obtained from the CDC. Exact protein concentrations of the toxins
were not available. Although a BCA protein assay was performed to determine toxin
protein concentrations, the results were inconclusive. Two of the three antibodies
received from the CDC had an affinity for the toxins and the commercial antibody
purchased from Accurate displayed no affinity for either toxin.
An ELISA verified antibody-toxin specificity; it was therefore determined that the
inability to generate a positive signal with the ELISA involved ganglioside-toxin
specificity. Initially, indirect ELISAs with the two gangliosides specific for botulinum
toxin, GT1b and Gd1b, passively adsorbed to the wells of a microtitre plate were
performed like those used to detect CT: neither showed any specificity for the toxin.
Detecting botulinum toxins with the use of a ganglioside, GT1b or GD1b, had been
achieved when it was incorporated in a liposome (1, 156). Creation of a liposome assay
was attempted. Several attempts to prepare liposomes incorporated with the ganglioside
failed. Custom liposomes were synthesized for the development of this assay by Dr.
Anup Singh at Sandia National Laboratories in Livermore, California (156).
GT1b was selected as the ganglioside for incorporation into the liposome. A
fluorophore conjugated to a phospholipid was required for the liposome. Cyanine 5
conjugated to a phospholipid was not available commercially; therefore, a fluorophore
with similar spectral characteristics to Cyanine 5 was selected. The Cyanine 5
fluorophore has an excitation at 635 nm with an emission at 670 nm and the Alexfluor
647 fluorophore has an excitation at 633/635 nm and an emission at 668 nm. Alexaflou647 conjugated to a phospholipid was available commercially from Molecular Probes and
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was selected for incorporation into the custom liposomes. The emission of the
Alexafluor 647 was out of the range of the Gemini fluorometer; therefore, ELISAs
typically used in assay development were not used to assay for ganglioside-toxin
specificity.
Initial work on the botulinum assay utilizing the Analyte 2000 was performed
using toxoid type A and the CDC-goat anti-type A antibody. Of the five possible
antigen-antibody combinations, the CDC-goat anti-type A antibody displayed the highest
affinity for its respective toxoid. The protein was passively adsorbed to the polystyrene
waveguide followed by incubation with the liposome. It appeared that this assay had
some potential in that there was a significant increase, of three- to five fold, in signal for
three out of four of the Analyte 2000 channels; however, the negative control channel
fluorescence signal doubled. The increase in signal for the negative control was
attributed to liposome sticking non-specifically to the polystyrene waveguide. Further
attempts were made in assay development with type A toxoid utilizing a biotinylated
capture antibody bound to the waveguide via a streptavidin bridge. Assays utilizing this
sandwich immunoassay format were unsuccessful as well: the LODs ranged in values
from 53-3100 pA. In order to try and reduce the LODs and obtain positive signals
several variables were manipulated: the concentration of the liposome was changed, the
toxin concentration was varied, specificity was tested using a different ligand, blocking
buffers and times were varied and different wash buffers were used. Regardless of the
variable altered, the assay continued to produce high LODs and negative results.
With the limitations of the assay utilizing type A toxoid, attempts were made to
try and develop the assay using type B toxoid. As illustrated previously, the antibody for
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the type B toxoid had a lower signal to noise ratio with the ELISA than the one used to
capture the type A toxoid. The assay followed the exact same format as the one used for
the type A toxoid: a sandwich immunoassay with the liposome as the detection
molecule. The assays were unsuccessful with LODs ranging from 163-3100 pA.
Limitations on the successful development of this assay for botulinum toxin could
not be resolved. The nonspecific binding of the liposomes to the polystyrene waveguide
and the inability to reduce the LODs contributed to the failed attempts to develop this
assay. Even though the assay itself was not successful, valuable information was
obtained from the study. It is not advisable for future assay development with the
Analyte 2000 to utilize liposomes as detection molecules. The liposomes are expensive
compared to most antibodies and they do not produce practical results. The research
conducted in this study with liposomes and the Analyte 2000 will hopefully influence
others not to utilize them as detection molecules. Even though gangliosides could not be
utilized in the botulinum assay, this does not rule out the possibility of using strictly
antibodies with this platform as capture and detector molecules.
Bioterrorism is a serious threat to the United States and to the world and cholera
has re-emerged as a major infectious disease worldwide. Documented events of
bioterrorism have occurred since 184 B.C. and, with the advances in science and
technology, transportation systems and the availability of select agents, such events
remain a possibility today (29). It is with the safety of the public health in mind that both
public and private sector entities are focusing on the development of technology to detect
biological agents (94). The evanescent wave fiber-optic biosensor represents one form of
technology with the capability to produce rapid, sensitive and specific assays for the
121

detection of CT. This research has shown that gangliosides can be used in a biosensor
assay to rapidly detect CT. The Analyte 2000 has the capability to produce near real-time
results with minimal sample preparation and the biosensor represents an alternative
method for the detection of bacterial products such as toxins.
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